

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁷ : C12N 15/12, 15/57, 15/67, 15/85, 9/64, C07K 14/72, C12Q 1/68, A61K 48/00		A1	(11) International Publication Number: WO 00/49147
			(43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/EP00/01368		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 18 February 2000 (18.02.00)			
(30) Priority Data: 199 07 099.7 19 February 1999 (19.02.99) DE 60/120,848 19 February 1999 (19.02.99) US			
(71) Applicant (for all designated States except US): THERAGENE BIOMEDICAL LABORATORIES GMBH [DE/DE]; Am Klopferspitz 19, D-82152 Martinsried (DE).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): HAUSER-FUNKE, Charlotte [DE/DE]; Romanstr. 95, D-80369 München (DE).			
(74) Agents: HELBING, Jörg et al.; von Kreisler Selting Werner, Deichmannhaus am Dom, D-50667 Köln (DE).			

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: HORMONE-HORMONE RECEPTOR COMPLEXES AND NUCLEIC ACID CONSTRUCTS AND THEIR USE IN GENE THERAPY



(57) Abstract

The invention relates to the use of a nucleic acid construct comprising at least one hormone responsive element and a transgene for preparing an agent for gene transfer. It further relates to particular nucleic acid constructs comprising at least one hormone responsive element and a transgene, wherein one of said at least one hormone responsive elements is not functionally linked to the transgene, vectors comprising such nucleic acid constructs and compositions of matter comprising such nucleic acid constructs wherein the hormone responsive elements of the constructs are coupled to a hormone-hormone receptor complex. The nucleic acid constructs, plasmids, and compositions of matter of the invention have applications in gene therapy, particularly in the treatment of human blood clotting disorders, such as hemophilia. They may also be used to up- or down-regulate target genes and for the delivery of vaccines.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MW	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MX	Malawi	US	United States of America
CA	Canada	IT	Italy	NE	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	PL	New Zealand		
CM	Cameroon		Republic of Korea	PT	Poland		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

Hormone -Hormone Receptor Complexes and Nucleic Acid Constructs and Their Use in Gene Therapy

5

Background of the Invention

1. Object of the Invention

The invention relates to the use of a nucleic acid construct comprising at least one hormone responsive element and a transgene for preparing an agent for gene transfer. It further relates to particular nucleic acid constructs comprising at least one hormone responsive element and a transgene, wherein one of said at least one hormone responsive elements is not functionally linked to the transgene, vectors comprising such nucleic acid constructs and compositions of matter comprising such nucleic acid constructs wherein the hormone responsive elements of the constructs are coupled to a hormone-hormone receptor complex. The nucleic acid constructs, plasmids, and compositions of matter of the invention have applications in gene therapy, particularly in the treatment of human blood clotting disorders, such as hemophilia. They may also be used to up- or down-regulate target genes and for the delivery of vaccines.

25 2. Summary of the Related Art

Gene therapy is a method that holds great promise for many diseases and disorders. In general, it involves the transfer of recombinant genes or transgenes into somatic cells to replace proteins with a genetic defect or to interfere with the pathological process of

CONFIRMATION COPY

an illness. In principle, gene therapy is a simple method. In practice, many disadvantages must still be overcome.

Research in gene therapy has concentrated on ways to most effectively incorporate DNA into cells of a patient. Viral vectors are currently the widely used vehicles in clinical gene therapy approaches. In terms of efficacy in gene expression, the viral delivery systems have major advantages over techniques using DNA-lipid formulations as delivery vehicles or over mechanical methods, such as the gene gun. Although there are a variety of viral systems tested for gene 10 therapeutical strategies, retroviral vectors and adenoviral vectors are presently the most widely used vehicles (Salmons, B. and Gunzburg, W. H., *Hum. Gene Ther.*, Vol. 4, 129, 1993; Kasahara, N. A., et al., *Science*, Vol. 266, 1373, 1994; Ali, M., et al., *Gene Ther.*, Vol. 1, 367, 1994.). Still, these systems have major disadvantages, such as 15 potential viral contamination. Other safety concerns continue to hamper the development of clinical application of gene therapy using these viral systems. For example, recombinant retroviruses have the disadvantage of random chromosomal integration, which may lead to activation of oncogenes or inactivation of tumor-suppressor genes. 20 Also, repetitive use of recombinant adenoviruses has caused severe immunological problems (Elkon, K. B. et al., *Proc. Natl. Acad. Sci. USA*, Vol. 94, 9814, 1997). The humoral response resulted in the production of antibodies to adenovirus proteins preventing subsequent infection. Immunosuppressive drugs may ameliorate these effects, but 25 they place an additional burden on the patient (Dai, Y., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 92, 1401, 1995).

Yet another viral delivery system involves adenoassociated virus (AAV). The AAV requires coinfection with an unrelated helper virus. Although such recombinant AAV virions have proven useful for 30 introducing several small gene sequences into host cells, gene

delivery systems based on those particles are limited by the relative small size of AAV particles. This feature greatly reduces the range of appropriate gene protocols. Moreover, the need to also use a helper virus adds a complicating factor to this delivery system (Muzychka, N., 5 *Curr. Top. Microbiol. Immunol.*, Vol. 158, 97, 1992).

Though safer, non-viral gene therapy approaches are also unsatisfactory. Problems with inefficient gene delivery or poor sustained expression are major drawbacks. Yet the methods available such as the direct injection of DNA into cellular compartments, or the 10 application of mixtures of DNA with cationic lipids or polylysine allowing the transgene to cross the cell membrane more easily, have not overcome these hurdles (Felgner, P., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 84, 7413, 1987; Behr, J.-P., *Bioconjugate Chemistry*, Vol. 5, 15 382, 1994).

Introduction of naked DNA (polynucleotide) sequences (including antisense DNA) into vertebrates, is reported to be achieved by injection into tissues such as muscle, brain or skin or by introduction into the blood circulation (Wolff, J. A., et al., *Science*, Vol. 247, 1990; Lin, H., et al., *Circulation*, Vol. 82, 2217, 1990; Schwartz, B., et al., 20 *Gene Ther.*, Vol. 3, 405, 1996). Also, a direct gene transfer into mammals has been reported for formulations of DNA encapsulated in liposomes and DNA entrapped in proteoliposomes containing receptor proteins. Although injected naked DNA leads to transgene expression, the efficiency is by far not comparable to viral-based DNA delivery 25 systems. A limitation of the method of naked DNA injection is the fact that transgene expression is dose-dependent. The gene expression is saturable, and an increase in the amount of DNA injected leads to decreased protein production per plasmid. Thus, protein expression can dramatically decrease, if the amount of DNA injected is above a 30 certain threshold.

Among the genetic disorders that the skilled artisan has sought to overcome using these prior art methods are those relating to blood clotting disorders, and in particular, hemophilia (Lozier, J. N. and Brinkhous, K. M., *JAMA*, Vol. 271, 1994; Hoeben, R. C., *Biologicals*, Vol. 23, 27, 1995). For example, hemophilia A and B are X-linked, recessive bleeding disorders caused by deficiencies of clotting factors VIII and IX, respectively (Sadler, J. E. et al., in: *The Molecular Basis of Blood Diseases*, 575, 1987). The incidence of hemophilia is about 1 in 5,000 male births. Hemophiliacs suffer from excessive bleeding due to the lack of clotting at the site of wounds. The inability to clot properly causes damage to joints and internal tissues as well as posing risks to the proper treatment of cuts.

Treatment of hemophilia A is possible by the administration of the blood clotting factor VIII. Until recently, factor VIII preparations had to be prepared by concentrating blood from donors, posing the risk of contamination by infectious agents, such as HIV and hepatitis. The gene for factor VIII has been cloned (e.g., Vehar et al., *Nature* Vol. 312, 337 1984) allowing for the production of a recombinant product. Although recombinant methods provide factor VIII of higher purity than blood concentrates, the exogenous supply of factor VIII to a patient still requires repeated doses throughout the lifetime of the patient, an inconvenient and expensive solution.

Other forms of hemophilia include hemophilia B, caused by a defect in the gene coding for Factor IX. The gene therapy systems described above have been attempted for the treatment of hemophilia A and B with factors VIII and IX, respectively. (See e.g., WO 94/29471). However, these systems have the disadvantages already discussed above.

On the other hand, the classical model of the action of hormones is based on the concept of binding interaction of the hormone to an

intracellular receptor, located in the cytoplasm or the nucleus (Evans, R., *Science*, Vol. 240, 889, 1988). These intracellular receptors remain latent until exposed to their target hormone. When so exposed, the hormone receptor changes its conformation after the 5 hormone is bound and translocates in the activated form into the cell nucleus where it binds as a dimer to hormone responsive elements in the promoter region of hormone-regulated genes (Beato, M., *Cell*, Vol. 56, 335, 1989; O'Malley, B., et al., *Biol. Reprod.*, Vol. 46, 163, 1992). The hormone responsive elements are enhancer elements 10 usually located in the 5' flanking region of the specific hormone-induced gene, i.e., are functionally linked to the specific hormone induced gene. DNA constructs comprising a hormone responsive element and a nucleic acid sequence encoding a protein of interest are disclosed in U.S. Pat. Nos. 5,688,677 and 5,580,722 and are taught to 15 be suitable for expression of the protein of interest.

An example of such intracellular receptors is the steroid receptor. Steroid receptors belong to a superfamily of ligand-dependent transcription factors characterized by a unique molecular structure. The centrally located highly conserved DNA-binding domain 20 defines this superfamily. The second important and relatively invariant region is the COOH-terminal ligand-binding domain. An example of such a receptor is the progesterone receptor mediated by the steroid progesterone. At the progesterone receptor, progesterone acts as a natural agonist whereas it displays potent antimineralocorticoid 25 properties both at the molecular and the systemic level. Besides classical effects on the uterus, antiepileptic, anxiolytic, hypnotic and anesthetic properties have been attributed to progesterone according to numerous studies.

Methods have been proposed for the use of mutant hormone 30 receptors, including mutant steroid receptors for gene therapy. For

example, such methods are disclosed in WO 93/23431, WO 98/18925, WO 96/40911. Moreover, WO 98/33903 discloses a genetic construct comprising a steroid responsive element from a tissue specific gene, a coding sequence, and an SV40 enhancer.

5

Brief Description of the Invention

The object of the present invention is to overcome the disadvantages of the previous gene therapy delivery systems. It was found that a hormone-hormone receptor complex possesses the ability to drag a nucleic acid construct having one or more hormone responsive element(s) through the cell membrane into a cell. It was also found that if the construct comprises further functional sequences besides the hormone responsive elements (hereinafter "transgenes"), the functional sequences exert their function. The hormone responsive element may also enhance the expression of the transgene. Moreover, it was found that steroid hormones are very effective mediators for the transfer of nucleic acid constructs through the cell membranes into a cell. The present invention thus provides

- (1) the use of a nucleic acid construct comprising at least one hormone responsive element (hereinafter referred to as "HRE") and a transgene for preparing an agent for gene transfer (said at least one HRE being functionally linked to the transgene or not);
- (2) a preferred embodiment of (1) above, wherein the agent further comprises a hormone-hormone receptor complex;
- (3) a nucleic acid construct comprising at least one HRE and a transgene, wherein one of said at least one HREs is not functionally linked to the transgene;
- (4) a vector comprising the nucleic acid construct of (3) above;

(5) a transformed cell or transgenic organism comprising the nucleic acid construct as defined in (3) above or the vector as defined in (4) above;

5 (6) a composition of matter comprising a nucleic acid construct comprising at least one HRE and a transgene as defined in (3) above and/or a vector as defined in (4) above, said at least one HRE being coupled to a hormone-hormone receptor complex;

(7) a preferred embodiment of (6) above, wherein the transgene is a gene encoding a blood clotting factor;

10 (8) a preferred embodiment of (7) above, wherein the blood clotting factor is factor IX;

(9) a preferred embodiment of (7) above, wherein the blood clotting factor is factor VIII;

15 (10) a pharmaceutical composition comprising the nucleic acid construct as defined in (3) above and/or the composition of matter as defined in (6) to (9) above;

(11) a method for preparing the composition of matter as defined in (6) above, which method comprises admixing the nucleic acid construct with the hormone receptor and the hormone;

20 (12) a method for gene transfer which comprises administering the agent as defined in (1) and (2) or the composition of matter as defined in (6) to (9) above to an organism or to a cellular system;

25 (13) a method for delivering into an organism or into a cellular system a nucleic acid encoding a transgene to be expressed in the cells of the organism or the cells of the cellular system, which method comprises administering an agent as defined in (1) above or composition of matter as defined in (6) to (9) above to the organism or to the cellular system so that the hormone in the composition interacts with the cell membrane and therewith enhances diffusion

and transport of the nucleic acid that is coupled to the hormone-hormone receptor complex across the membrane and into the cell;

5 (14) a method of treating blood clotting disorders comprising administering a therapeutically effective amount of the composition of matter as defined in (7) above to an organism or to a cellular system;

(15) a method of treating hemophilia B, comprising administering a therapeutically effective amount of the composition of matter as defined in (8) above to an organism or to a cellular system;

10 (16) method of treating hemophilia A, comprising administering a therapeutically effective amount of the composition of matter as defined in (9) above to an organism or to a cellular system;

(17) use of a steroid hormone for preparing an agent for gene transfer; and

15 (18) a method for gene transfer which comprises administering a nucleic acid construct to an organism or to a cellular system, wherein the nucleic acid construct contains a transgene and is encapsulated in a steroid hormone.

20 In a preferred embodiment of (1) to (16) above the hormone responsive element is a steroid responsive element (SRE), most preferably a progesterone responsive element (PRE). In embodiments (2) and (6) to (16) the receptor preferably is a steroid receptor, most preferably, a progesterone receptor. Similarly, the hormone is preferably a steroid, most preferably, progesterone.

25 The present invention thus provides a delivery system for gene therapy that should overcome the prior art disadvantages. The presence of the hormone responsive element on the nucleic acid carrying a transgene encourages the binding of a hormone-hormone receptor complex. Thus, the present invention uses the activated 30 hormone receptor as a link (or binding compound) between the

nucleic acid carrying the transgene and the hormone known to interact with the cell membrane. The general known biological activity mediated by the HREs is not the primary effect utilized in the present invention, but might be an additional effect when regulation of the transgene is desired. The general principle is depicted in Figure 1. The hormone responsive element is preferably present as a nucleic acid dimer sequence or nucleic acid multimer sequence. Even in an inverse orientation, the hormone responsive element will exert its proper function. The hormone-hormone receptor complex contains a hormone receptor that becomes activated after binding of its specific hormone. The hormone receptor in the activated state is able to recognize and bind to its specific hormone responsive element, which in the present invention is present within the nucleic acid comprising the desired transgene, e.g., a human blood-clotting factor.

Vaccination is another aspect of the embodiment (12) defined above. Introducing a nucleic acid construct or composition of matter of the invention comprising a gene for an antigen or containing a viral sequence into a cell (DNA vaccines) using the method mentioned above may also provide a way to stimulate the cellular immune response.

Brief Description of the Drawings

Figure 1 shows the concept of gene transfer of the present invention (with HRE = hormone responsive element, HR = hormone receptor, H = hormone, blank circles = lipophilic matrix).

Figure 2 is a diagram of the vector pTGFG1.

Figure 3 is a diagram of the vector pTGFG5.

Figure 4 is a diagram of the vector pTGFG20.

Figure 5 is a diagram of the vector pTGFG33.

Figure 6 is a diagram of the vector pTGFG36.

Figure 7 is a diagram of the vector pTGFG53.

Figure 8 is a diagram of the vector pTGFG64.

Figure 9 is the DNA sequence of vector pTGFG36 (SEQ ID NO: 1).

5 Figure 10 shows the protein sequence of factor IX encoded by vector pTGFG36 (SEQ ID NO: 2).

Figure 11 shows a GFP concentration curve for cell homogenates after transfection with pTGFG5 and pTGFG20, respectively.

10 Figure 12 shows corresponding light (a and c) and fluorescent (b and d) micrographs of HeLa cells transfected with pTGFG5 (a and b) and pTGFG20 (c and d), respectively.

Figure 13 shows the amount of GFP expressed by utilizing the favoured vectors of the invention in a transfection experiment.

15 Relative fluorescence units from mock and background can be clearly separated.

Figure 14 shows the additive effect of human clotting factor IX on clotting activity of mouse blood.

20 Figure 15: hPR (A-form) was expressed in insect cells and purified by cobalt²⁺ affinity chromatography as described in Example 5. The final preparation (85µg protein) was separated on a denaturing 7,5% SDS-polyacrylamid gel, followed by staining with coomassie® R250 (lane A) or western blotting with hPR-specific staining (lane C).

25 Lane B: Molecular mass standard. Arrows indicate the two highly enriched protein species (94 and 74 kDa) accessible to immunodetection.

Figure 16: Domain structure of hPR-B (numbers on the top of the bar represent amino acid positions within the polypeptide sequence).

Figure 17 shows the mean values of the difference in the clotting time of Example 9.

30 Figure 18 shows the clotting time detected in Example 9.

Figure 19 shows the activity of human progesterone receptor as determined in Example 8.

Figure 20: shows the amino acid sequence of the hPR B-Form. The start methionine 165 of the hPR A-Form is underlined (SEQ ID NO: 5 18).

Figure 21 shows the nucleic acid sequence of the mRNA coding for hPR. The reading frame for the hPR B-form starts at position 176, the reading frame for the hPR A-Form at position 668. The respective start codons ATG are underlined (SEQ ID NO: 19). The sequences of 10 Figures 20 and 21 are taken from Genbank, accession number AF016381.

Detailed Description of the Invention

15 1. Definitions

"Nucleic acid" means DNA, cDNA, mRNA, tRNA, rRNA. The nucleic acid may be linear or circular, double-stranded or single-stranded.

"Nucleic acid construct" refers to a composite of nucleic acid 20 elements in relation to one another. The nucleic acid elements of the construct may be incorporated into a vector in such an orientation that a desired gene may be transcribed, and if desired, a desired protein may be expressed.

"Transgene" refers to a functional nucleic acid sequence which is 25 transcriptionally active (with or without regulatory sequences).

"Gene transfer" includes "gene therapy".

"Hormone responsive element" (HRE) refers to regions of nucleic acids, and in particular, DNA, which regulate transcription of genes in response to hormone activation. HREs are typically about 30 10-40 nucleotides in length, and more usually, about 13-20 nucleotides in

length. As explained above, HREs become activated when a hormone binds to its corresponding intracellular receptor causing a conformational change, so that the receptor has increased affinity for the HRE and binds to it. The HRE, in turn, stimulates transcription. A "steroid responsive element" (SRE) is an HRE that regulates transcription of genes in response to steroid activation. A "progesterone responsive element" (PRE) is an HRE/SRE that regulates transcription of genes in response to progesterone activation.

A "hormone receptor" refers to a receptor which binds to and is activated by a hormone. A "steroid receptor" refers to a receptor which binds to and is activated by a steroid hormone. A "progesterone receptor" is a receptor which binds to or is activated by the steroid hormone progesterone.

"Functionally linked" refers to configurations of the nucleic acid construct, where the HRE (or SRE/or PRE) is located within the construct so that it can stimulate transcription of the transgene. "Not functionally linked" refers to configurations where the HRE is so remotely located from the transgene that it cannot stimulate its transcription.

"Gene" refers to DNA sequence encoding a polypeptide, optionally including leader and trailer sequences and introns and exons.

"Vector" refers to any genetic construct, such as a plasmid, phage, cosmid, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells. The term includes cloning and expression vehicles.

"Promoter" refers to a region of regulatory DNA sequences for the control of transcription of a gene to which RNA polymerase binds.

The promoter forms an initiation complex with RNA polymerase to initiate and drive transcription activity. "Enhancers" may activate the complex or "silencers" may inhibit the complex. A "tissue-specific promoter" is a promoter found in the DNA of tissue for transcription of genes expressed in this specific tissue.

"Organism" refers to a multicellular living entity including vertebrates such as mammals (especially humans, cattle, rodents, dogs) and invertebrates.

"Cellular system" includes cell cultures, e.g., primary cell cultures (especially those suitable for reimplantation), stem cells, blood cells, tissue samples and whole organs and immortalized cell cultures.

"Therapeutically effective dose" of the products of the invention refers to a dose effective for treatment or prophylaxis, for example, a dose that yields effective treatment or reduction of the symptoms of hemophilia. It is also a dose that measurably activates expression of a target gene as determined by measurements of target protein levels, or a dose that is predictable to be effective for treatment or prophylaxis by extrapolating from *in vitro* or *in vivo* data. The determination of a therapeutically effective dose is within the purview of one skilled in the art.

"Encodes" or "encoding" refers to a property of the nucleic acid sequence of being transcribed (in case of DNA) or translated (in the case of mRNA) into a polypeptide *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences.

For the purposes of this application, "express", "expressing" or "expression" shall refer to transcription and translation of a gene encoding a protein.

2. Detailed Description and Examples

As stated above, an object of the present invention is to provide a new and improved delivery system for gene therapy. The invention thus provides nucleic acid constructs comprising at least one HRE and a transgene wherein one of said at least one HREs is not functionally linked to the transgene, and compositions of matter comprising such nucleic acid construct wherein said at least one HRE is coupled to a hormone-hormone receptor complex (embodiments (3) and (6) defined above). A preferred embodiment of the nucleic acid construct and of the composition of matter of the invention is one where the hormone responsive element is a steroid responsive element (SRE), and the receptor is a steroid receptor. Most preferably, the hormone responsive element is a progesterone responsive element (PRE), and the receptor is a progesterone receptor.

Potential HREs for use in the present invention have been previously described. For example, GREs (Scheidereit, C., et al., *Nature*, Vol. 304, 749, 1983; von der Ahe, D., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 83, 2817, 1986), EREs or PREs (Chambon, P., et al., *Rec. Prog. Horm. Res.*, Vol., 40, 1, 1984; Klock, G., et al., *Nature*, Vol. 329, 734, 1987). As already stated above, the most preferred HRE for the invention is a PRE. Specifically, the preferred PRE is described in Example 1, i.e., is the double stranded DNA sequence comprised of SEQ ID NOS: 3 and 4. The nucleic acid for use in the invention comprises at least one hormone responsive element. Preferred is a nucleic acid comprising more than one HRE. For example, the nucleic acid may comprise three to ten, preferably three to five HREs. The most preferred embodiment is a nucleic acid comprising three to five PREs.

Potential hormone receptors for use in the present invention are, for example, estrogen receptors, mineralocorticoid receptors,

glucocorticoid receptors, retinoic acid receptors, androgen, calcitriol, thyroid hormone or progesterone receptors and orphan receptors. Such receptors have been previously described. (Green, S., et al., *Nature*, Vol. 320, 134, 1986; Green, G. L., et al., *Science*, Vol. 231, 5 1150, 1986; Arriza, J. L., et al., *Science*, Vol. 237, 268, 1987; Hollenberg, S. M., et al., *Nature*, Vol. 318, 635, 1985; Petkovitch, M., et al., *Nature*, Vol. 330, 444, 1987; Giguere, V., et al., *Nature*, Vol. 330, 624, 1987; Tilley, W., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 86, 10 327, 1989; Baker, A. R., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 85, 3294, 1988; Weinberger, C., et al., *Nature*, Vol. 324, 641, 1986; Sap, J., et al., *Nature*, Vol. 324, 635, 1086; Misrahi, M., et al., *Biochem. Biophys. Res. Commun.*, Vol. 143, 740, 1987; Kastner, P., et al., *Cell*, 15 Vol. 83, 859, 1995). These receptors may be from human or other mammalian sources, although human is preferred. Nucleotide and/or amino acid sequences of human steroid receptors are available in the GenBank: mineralocorticoid receptor: M16801; glucocorticoid receptor α : M10901; glucocorticoid receptor α_2 : U01351; glucocorticoid receptor β : M11050; retinoic acid receptor α : AF088888 (exon 1), AF088889 (exon 2), AF088890 (exon 3), AF088891 (exon 4), 20 AF088892 (exon 5 and 6), AF088893 (exon 7), AF088894 (exon 8), AF088895 (exon 9 and complete cDNA); retinoic acid receptor γ : M24857; androgen receptor: M27423 (exon 1), M27424 (exon 2), M27425 (exon 3), M27436 (exon 4), M27427 (exon 5), M27428 (exon 6), M27429 (exon 7), M27430 (exon 8); thyroid hormone receptor α_1 : 25 M24748, thyroid hormone receptor α_2 : J03239; progesterone receptor: AF016381; somatotropin receptor: J00148; vitamin D receptor (calcitriol receptor): J03258.

The skilled person will understand that expression of the receptor proteins can be achieved by standard methods, e.g. via PCR-cloning of the known cDNAs from cDNA libraries and overexpression of 30

the corresponding proteins in suitable expression vectors, such as, for example, the vectors of the present invention, in suitable host cells, e.g., COS cells. Accordingly, subsequent purification of the cytosolic fraction can be achieved by routine methods such as affinity chromatography purification. For this purpose, various suitable antibodies against the desired receptor are commercially available. For example, polyclonal antibodies against the mouse progesterone receptor that have a sufficiently high cross-reactivity for the human protein are available from Dianova (Hamburg, Germany). Likewise, further purification can be achieved by standard methods, e.g., chromatographical methods such as ion-exchange chromatography and/or FPLC.

The most preferred receptor is the progesterone receptor. Preferably, the receptor is a human progesterone receptor. Such a human progesterone receptor (from T47D human breast cancer cells) is disclosed in US Patent No. 4,742,000, and cells expressing this receptor have been deposited (ATCC deposit number HTB, 133). As already described above, it would be routine to purify such a receptor from the cytosol using receptor specific antibodies. In addition, US Patent No. 4,742,000 discloses a method for purification of the human progesterone receptor using a specific steroid affinity resin (cf. Grandics et al., *Endocrinology*, Vol. 110, 1088, 1982).

Briefly, the cytosolic fraction of the T47D cells is passed over Sterogel, a commercial preparation of deoxycorticosterone coupled to Sepharose[®] 2B that selectively binds the progesterone receptor. After washing with loading buffer, the bound receptor is eluted with a buffer containing progesterone. The eluted steroid-receptor complex is then chromatographed on DEAE-Biogel and eluted stepwise with a buffer containing 0.2M NaCl. Subsequently, the bound progesterone can be

readily exchanged. As described above, further purification can be achieved by routine methods well-known to the skilled person.

An alternative method is disclosed in Example 5.

The structure of the hPR polypeptide is depicted in Fig. 16. The hPR polypeptide is composed of distinct structural domains. Naturally the human progesterone receptor (hPR) is expressed as two different sized proteins termed hPR-B (120 kDa) and hPR-A (94 kDa). HPR-A is a truncated but otherwise identical form of hPR-B, that is missing 165 the N-terminal amino acids (see Fig. 20, SEQ ID NO: 18). Both forms 10 seems to be indistinguishable regarding their progesterone or DNA binding properties. In human cells the A and B forms of hPR are produced from the same gene by alternate initiation of translation at two different AUG start sites within the same RNA transcript. As it was reported earlier hPR-A and B can be expressed in *Spodoptera frugiperda* (Sf9) cells as biological fully active polypeptides 15 (Christensen *et al.*, Mol. Endocrinol. 5, 1755ff (1991); Elliston *et al.*, JBC 267, 5193-5198 (1992)).

The carboxyl terminus of the hPR polypeptide as shown in Fig. 16 comprises a progesterone binding domain (PBD) but also contains 20 sequences responsible for the association with heat shock proteins and receptor dimerization. The hinge region provides a flexible link between the DNA-binding domain (DBD) and the PBD but is also thought to contain elements for receptor dimerization as well as nuclear localization. Binding of the hPR to its corresponding target 25 sites at the chromosomal DNA (PREs, Progesterone Responsive Elements) is known to be mediated by the DBD. The remaining N-terminal trans-activation domain (TAD) consists of regions specific for the *in vivo* function of the hPR as a transcriptional gene activator.

Even though the N-terminus also seems to contribute directly to 30 the homodimerization of hPR after progesterone binding, it has been

demonstrated that a fragment comprising only the hinge region and the PBD was the minimal C-terminal fragment to mediate progesterone dependent hPR-hPR-interaction (Tetel *et al.*, Mol. Endocrinol. 11, 1114ff. (1997). It is believed that genetically 5 engineered hPR polypeptides lacking either in part or completely the TAD (amino acids 1 to 556) might be expressed as structurally stable and fully soluble dimers in the presence of progesterone. Complexes with such a truncated hPR (provided that said truncated hPR exhibits 10 DNA-binding activity as well as progesterone-binding activity) may functionally replace the complexes with the full length form of the described recombinant hPR-A or hPR-B proteins, since still mediating the contact between the plasmid DNA and the progesterone. Thus, the hPR in embodiments (2) and (6) to (16) of the invention preferably is 15 a PR comprising nucleic acids 557 to 933 of natural hPR shown in SEQ ID NO: 18.

Effective expression of such a truncated version of hPR is possible in the baculovirus system but also in other eukaryotic expression systems, such as cultivated mammalian cells or yeast cells. Furthermore, also an *E. coli* overexpression strain is a possible 20 system for the production of those polypeptides. In this case, the fusion of such a truncated hPR-version to a suitable polypeptide sequence, e.g. a histidine containing sequence or the GST (glutathion S- transferase) protein, might be helpful to overcome insolubility problems as well as to facilitate the isolation and purification of the 25 expressed protein.

Mutated versions of these receptors and derivatives thereof, that still retain the function of the receptors to bind a ligand and thereby become activated and bind DNA and regulate transcription, may also be employed in the invention. Such derivative may be a 30 chemical derivative, variant, chimera, hybrid, analog, or fusion.

The third component of the gene transfer system of the invention is the hormone. The hormone in the agent of embodiment 2 and in the composition of matter of embodiment (6) include synthetic and natural hormones, preferably steroid hormones, such as estrogen, 5 testosterone, glucocorticoid, androgen, thyroid hormone, and progesterone or derivatives thereof. These are widely available. Progesterone is most preferred. For example, natural micronized progesterone is the preferred progesterone from which has been marketed in France since 1980 under the trademark of UTROGESTAN® 10 and is still available in Germany under the trademark UTROGEST®. Its properties are similar to the endogenous progesterone, in particular, it has antiestrogen, gestagen, slightly antiandrogen and antimineralcorticoid properties. The natural micronized progesterone in said marketed products is dispersed in a matrix as described 15 hereinbelow.

The above micronized progesterone has advantages that make it a suitable carrier for genes or nucleic acid constructs to target cells. Specifically, the synergistic effect of the double process of micronization and suspension in long-chain fatty acids residues of an 20 oil results in increasing progesterone absorption. It has been demonstrated that after oral administration of 100 mg of UTROGESTAN®, peak plasma progesterone levels were obtained after 1-4 hours in most cases (Padwick, M. L., et al., *Fertil. Steril.*, Vol. 46, 402, 1986). Later on, the levels declined substantially, although they 25 were still elevated at 12 hours. Even at 84 hours the levels were slightly higher than baseline. A U.S. kinetic study confirmed earlier work demonstrating the bioavailability of oral micronized progesterone. They showed a peak effect at 2 hours followed by rapid decrease in plasma progesterone level (Simon, J. A., et al., *Fertil.*, 30 *Steril.*, Vol., 60, 26, 1993).

A further advantage of using progesterone as a carrier is the low level of disadvantageous side effects. Orally administered progesterone adversely affects neither plasma lipids (Jensen, J. et al., Am. J. Obstet. Gynecol., Vol. 156, 66, 1987) nor carbohydrate metabolism (Mosnier-Pudar, H. et al., Arch. Mal. Coeur, Vol 84, 1111, 1991). Further, progesterone does not affect liver enzymes (ASAT, ALAT, AFOS), sex-hormone binding-globulin (SHBG) synthesis or HDL-cholesterol levels at daily doses of 200 mg and 300 mg. Although the plasma levels of deoxycorticosterone may increase substantially during UTROGESTAN® treatment, there are strong indications that the mineralocorticoid effects of this progesterone metabolite are completely counteracted by the anti-mineralocorticoid effects of progesterone itself. This is apparent from a comparative study (Corvol, P., et al., In: Progesterone and progestins. Raven Press, New York, 179, 1983) in which oral UTROGESTAN® was capable of antagonizing the mineralocorticoid effects of 9- α -fluorohydrocortisone.

In the agent of embodiment (2) and in the composition of matter of embodiment (6) of the invention the molar ratio of HRE (or SRE/or PRE) within the nucleic acid construct to hormone receptor is preferably from 1:1 to 1:10, more preferably from 1:2 to 1:5. On the other hand, the molar ratio of hormone to hormone receptor is preferably at least 1000:1, more preferably at least 10000:1. Thus, the hormone is present in a large excess relative to the hormone receptor and the HRE, which is desirable in view of the ability of the hormones to transfer nucleic acid constructs through cell membranes.

The skilled artisan will appreciate that the agent of embodiments (1) and (2) and the pharmaceutical composition of embodiment (10) may contain other components capable of assisting in introducing the nucleic acid into a cell for the purpose of gene therapy (matrix compounds). Specifically, the agent and the composition, especially

the hormone component thereof, may contain the following matrix compounds: glucose and related compounds (such as D-sorbitol, D-mannitol); solubilizing adjuvants (such as alcohols, e.g., ethanol); polyhydric compounds such as glycerine, polyethylene glycol and 5 polypropylene glycol; nonionic surface active compounds, ionic surface active compounds such as lecithin; oily compounds such as sesame oil, peanut oil soybean oil, corn oil, etc.; starches and their derivatives such as cyclodextrines and hydroxyalkylated starches; stabilizers such as human serum albumin, preservatives such as benzyl alcohol and 10 phenol; and the like. The preferred matrix contains β -cyclodextrine, glycerine, lecithin and/or corn oil. For example, the pharmaceutical composition of hormone-hormone receptor nucleic acid complex of the invention may be provided orally to humans or animals as a gelatin capsule. Progesterone therein (preferably in micronized form) could 15 be present in a concentration of 50 to 1000 mg, preferably 200 –300 mg dissolved in a 35 % or 40 % β -cyclodextrin solution or in cornoil or glycerol with peanut oil together with lecithin.

Alternatively, when - due to the selection of appropriate matrix components - the pharmaceutical composition is in a pasty, gel-like 20 form, it may be provided topically.

The nucleic acid construct of embodiments (1) to (16) of the present invention may - aside from the transgene and the HREs, SREs, or PREs already disclosed above - further contain promoter, enhancer, and/or silencer sequences. The promoter may be ubiquitous 25 or tissue-specific. Of the ubiquitous promoters, the CMV promoter is most preferred. However, a tissue-specific promoter is preferred over a ubiquitous promoter. For example, the tissue-specific promoters envisioned for the instant invention include α_1 -antitrypsin (further promoters).

1 The nucleic acid construct may further comprise additional
2 sequences such as the ampicillin resistance gene. Other reporter
3 sequences known to the skilled artisan may also be included, such as,
4 for example, the green fluorescent protein (GFP), luciferase, β -
5 galactosidase or chloramphenicolacetyltransferase (CAT). As an
6 enhancer sequence, the SV40 intron and SV40 Poly A are most
7 preferred. The nucleic acid construct may further contain inducible
8 promoters such as, for example, a MMTV (Mouse Mammary Tumor
9 Virus) promoters inducible via glucocorticoides and Ecdyson-inducible
10 insect promoters.

15 A preferred nucleic acid construct contains sequentially from the
16 5' to the 3' end: a PRE, a CMV promoter, a gene of interest, SV40
17 Intron and SV40 poly A enhancer sequence, and an ampicillin
18 resistant gene. Further PREs are evenly distributed on the vector
19 backbone.

20 The nucleic acid construct may further contain origin of
21 replication sequences (especially eukaryotic origin of replication
22 sequences), elements for gene targeting, integrational sequences
23 (e.g., AAV-ITR, transposon IS), 3'-UTR, "switch" systems (e.g., TET
24 system, Cre/loxP or Flp/ftr system).

25 The transgene may be chosen from those encoding proteins
26 lacking in a variety of genetic disorders or involved in conditions
27 related to inappropriate responses to hormones, for example,
28 hormone-dependent cancers such as breast, ovarian, and endometrial
29 cancers and prostate cancer. The transgene may also be used to
30 replace a defective gene resulting in such genetic disorders as
hemophilia, von Willebrand disease, and cystic fibrosis. The transgene
includes mutations of such gene or a gene encoding a fusion product.
The nucleic acid construct of the present invention may comprise
more than one transgene.

In particular, the transgene may replace genes for a blood clotting factor, and preferably a human blood-clotting factor. The genes encoding factor VIII and factor IX (shown in Fig. 2, SEQ ID NO: 2), involved in hemophilia A and B, respectively, are good candidates for the invention. Other candidates include the gene encoding von Willebrand factor, factor IV, factor X, or protein C.

Other useful transgenes include, but are not limited to, hormone genes such as the genes encoding for insulin, parathyroid hormone, luteinizing hormone releasing factor (LHRH), α and β seminal inhibins and human growth hormone; hormone receptor genes such as the glucocorticoid receptor, the estrogen receptor, the progesterone receptor, the retinoic acid receptor; growth factors such as vascular endothelial growth factor (VEGF), nerve growth factor, epidermal growth factor; enzyme genes; genes encoding cytokines or lymphokines such as interferons, granulocytic macrophage colony stimulating factor (GM-CSF), colony stimulating factor-1 (CSF-1), tumor necrosis factor (TNF), and erythropoietin (EPO); genes encoding inhibitor substances such as α_1 -antitrypsin, and genes encoding substances that function as drugs, e. g., genes encoding the diphtheria and cholera toxins, ricin or cobra venom factor. Also, antisense sequences may be administered as genetic material.

Another aspect of the present invention is vectors comprising the nucleic acid constructs of embodiment (3) of the present invention. These vectors may be used in the composition matter of embodiment (6) of the present invention. Preferably, however, the nucleic acid sequence for use in the invention is circular rather than linear. The vectors may be capable of expressing the nucleic acid in the nucleic acid construct transiently or permanently (including episomally). As noted above, the nucleic acid construct therein may further contain additional elements.

The composition of matter of embodiment (6) of the invention can be prepared by admixing the nucleic acid construct with the hormone receptor and the hormone. Preferably, an aqueous solution of nucleic acid construct was added to the oily suspension containing 5 the hormone at ambient temperature under stirring.

Embodiment(s) of the invention relates to transfected and transformed cells or transgenic organism comprising these vectors and/or nucleic acid constructs. Within the scope of this invention, a transfected cell is one in which foreign DNA has been incorporated. 10 Methods of transfection may include microinjection, CaPO_4 precipitation, electroporation, liposome fusion, or gene gun.

Transformation refers to introducing genetic material into a cell, such as the vectors or nucleic acid constructs of the invention, rendering the cell transiently or permanently altered so that the cell 15 expresses a specific gene product or is otherwise altered in its expression. Transformation may be achieved by *in vivo* or *in vitro* techniques, although *in vivo* transformation is preferred.

A further embodiment of the present invention is pharmaceutical compositions comprising a therapeutically effective dose of the nucleic 20 acid constructs of the invention and a hormone. The hormone is preferably a steroid, and most preferably, progesterone, as described above. The dose is dependent on the condition to be treated, the characteristics of the patient, and the result sought to be achieved. Determining dosage is within the realm of the skilled artisan.

25 The pharmaceutical composition (or, alternatively, the composition of matter, the nucleic acid construct, or the vector) of the present invention may be administered orally, intravenously, intramuscularly, subcutaneously, topically, through mucosa (including buccal, nasal spray) or by gene gun. Oral administration (of a

micronized hormone dispersion) is preferred. Delivery may be systemic or directed at certain tissue.

The invention further includes a method of introducing into a cell a nucleic acid construct encoding a gene of interest, e.g., a human blood-clotting factor, to express the blood-clotting factor in the cell. In this method, the nucleic acid encoding a human blood-clotting factor is combined with a nucleic acid construct comprising at least one hormone responsive element (HRE), preferably a progesterone responsive element.

The mixture of nucleic acid bound to the hormone-hormone receptor complex together with an excess of hormone, preferably progesterone, will be used to introduce the nucleic acid into a cell by various methods known to the skilled artisan and outlined above. The cell-uptake will be stimulated by the interaction of the hormone with the cell membrane. The hormone or steroid interacts with the lipid bilayer of the cell membrane not only through membrane perturbation but also through activation of certain hormone- or steroid-sensitive membrane receptors. This has been demonstrated for progesterone and other steroids. Last but not least, it is known that hormones are able to cross the cell membrane by diffusion. In the present invention, the nucleic acid bound to the hormone-hormone receptor complex should be transported through the membrane during the process of diffusion or uptake.

Another aspect of the invention is a method of treating a blood clotting disorder by administering a therapeutically effective amount of the composition of matter of the invention to an organism. This method involves the administration and dosage considerations already discussed.

Embodiments (17) and (18) of the invention pertain to the use of a steroid hormone for preparing an agent for gene therapy and/or

gene transfer and to method for gene therapy and/or gene transfer which comprises administering a nucleic acid construct to an organism or to a cellular system, wherein the nucleic acid construct contains a transgene and is encapsulated in a steroid hormone. Suitable steroid 5 hormones are enumerated hereinafter. The preferred steroid hormone in said embodiments of the invention is a natural micronized steroid hormone, in particular a natural micronized progesterone. In a preferred embodiment, the micronized hormone is solubilized/dispersed in a lipophilic matrix as described hereinafter.

10 Experiments have been performed to illustrate the technical aspects of the present invention. These experiments are described in examples 1 to 9 below. The skilled artisan will be readily recognize that the invention is not limited to these examples.

15 **Examples**

Example 1: Construction of Vectors

Production of the vector pTGF_{G1}: The vector pUC19 (MBI Fermentas) 20 was digested with XbaI, treated with Klenow enzyme and religated. This XbaI deleted vector was then digested with EcoRI, treated with Klenow enzyme and religated in order to delete the EcoRI site. For insertion of a XbaI site in the SacI site of this vector it was digested with SacI, treated with T4-polymerase, dephosphorylated with alkaline 25 phosphatase and ligated with the XbaI-linker CTCTAGAG (Biolabs #1032). Another XbaI-site was inserted by digesting the newly produced vector with HindIII, treating it with Klenow, dephosphorylating it with alkaline phosphatase and ligating it with the XbaI-linker CTCTAGAG (Biolabs #1032). This vector was named 30 pUC19/X.

In order to destroy the XbaI-site present in the vector phGFP-S65T (Clontech) this vector was digested with XbaI, treated with Klenow enzyme and religated resulting in the vector pGFP/0. A 2.3 kb fragment containing the GFP-Gene was isolated after digesting pGFP/0 with MluI, treating it with Klenow enzyme and digesting it with BamHI. This fragment was inserted into the multiple cloning site of the vector pUC19/X which was digested with SalI, treated with Klenow enzyme and digested with BamHI. The resulting vector was named pTGFG1 (Figure 2).

Starting with this vector all the vectors described in Table 1 were obtained. At the restriction sites for PstI, KpnI, EheI, EcoO109 and/or SapI a PRE(ds) was inserted giving rise to plasmids carrying the GFP gene and up to five PREs. By exchanging the GFP gene with a FIX gene a set of FIX expression plasmids were obtained. By excising the GFP gene the cloning vectors without a transgene were obtained.

Production of the insert PRE(ds): The oligonucleotides (Metabion) PRE-S (5'-GGG GTA CCA GCT TCG TAG CTA GAA CAT CAT GTT CTG GGA TAT CAG CTT CGT AGC TAG AAC ATC ATG TTC TGG TAC CCC-3';
20 SEQ ID NO: 3) and
PRE-AS (5'-GGG GTA CCA GAA CAT GAT GTT CTA GCT ACG AAG CTG ATA TCC CAG AAC ATG ATG TTC TAG CTA CGA AGC TGG TAC CCC-3';
SEQ ID NO: 4)
were hybridized and phosphorylated by kinase reaction, resulting in
25 the insert PRE(ds).

Production of the vector pTGFG5: The vector pTGFG1 was digested with EcoO109I, treated with Klenow enzyme and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert,

resulting in the vector pTGFG5 (Figure 3), i.e., a vector which carries a PRE at position C of Fig. 2.

Production of the vector pTGFG20: The vector pTGFG1 was digested with KpnI, treated with T4-polymerase and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert, resulting in the vector pTGFG7. This vector pTGFG7 was digested with PstI, treated with T4-polymerase and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert, resulting in the vector pTGFG11. Subsequently, pTGFG11 was digested with EcoO109I, treated with Klenow enzyme and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert, resulting in the vector pTGFG20 (Figure 4). This vector carries a PRE at positions A, B and D of Fig. 2.

15

Production of the vector pTGFG33: In a similar manner PRE(ds) were inserted at the restriction sites for PstI, KpnI, EheI, EcoO109 and SapI in vector pTGFG1 giving rise to the plasmid pTGFG33 (Figure 5), which is a vector that carries the GFP gene and five PREs, one each in position A, B, C, D, E (Figure 2).

Production of the vectors pTGFG36, pTGFG53 and pTGFG64: The vector pUC19 (MBI Fermentas) was digested with SalI, treated with Klenow enzyme and dephosphorylated with alkaline phosphatase. It was ligated to the NotI-linker GCGGCCGC (Biolabs # 1045), resulting in the vector pUC19/N.

A 1.4 kb fragment containing the open reading frame of the human clotting factor IX, isolated from a human cDNA library (see example 2), was inserted into the PstI-site of the vector pUC19/N which was digested with PstI, treated with T4-polymerase and

25

30

5 dephosphorylated with alkaline phosphatase. From the resulting vector pUC19/N-FIX a 1.4 kb fragment containing the open reading frame of the human clotting factor IX was cut out by double-digestion with Hind III and NotI. This fragment was ligated to the 4.3 kb fragment of the HindIII and NotI double-digested vector pTGFG5 resulting in the vector pTGFG36 shown in Figure 6. This vector is a preferred one for delivery of Factor IX into the cell, and its DNA sequence is provided in Figure 9 (SEQ ID NO: 1).

10 In a similar manner plasmids pTGFG53 and pTGFG64 (shown in Figures 7 and 8) were obtained by exchanging the GFP gene in plasmids pTGFG20 and pTGFG33 by the FIX gene.

15 Production of the insert ALLG(ds): The oligonucleotides (Metabion) ALLG1/1 (5'-AGC TTG ACC TCG AGC AAG C-3') (SEQ. ID NO: 5) and ALLG2 (5'-GGC CGC TTG CTC GAG GTC A-3') (SEQ. ID NO: 6) were hybridized and phosphorylated by kinase reaction, resulting in the inserts ALLG(ds). The insert ALLG (ds) was constructed to introduce into the vector of choice a sequence with a multiple cloning site for the possible introduction of other transgenes.

20 Table 1 gives an overview of the available vectors with different transgenes and a different number of PREs in various positions. The positions of the PREs are given according to Figure 2. For the underlined vectors a map is provided (Figures 3 to 8).

Table 1: Vectors of the invention

Plasmid	Trans-gene	PRE	Plasmid	Trans-gene	PRE	Plasmid	Trans-gene	PRE
pTGFG0	--	--	pTGFG18	GFP	BDE	pTGFG34	FIX	E
<u>pTGFG1</u>	GFP	--	<u>pTGFG19</u>	GFP	BCD	pTGFG35	FIX	A
pTGFG2	FIX	--	<u>pTGFG20</u>	GFP	ABD	<u>pTGFG36</u>	FIX	D
pTGFG3	GFP	E	pTGFG21	GFP	CDE	pTGFG37	FIX	C

pTGF4	GFP	A	pTGF22	GFP	ACD	pTGF38	FIX	B
<u>pTGF5</u>	GFP	D	pTGF23	GFP	ABC	<u>pTGF53</u>	FIX	ABD
pTGF6	GFP	C	pTGF24	GFP	ABE	<u>pTGF64</u>	FIX	ABCDE
pTGF7	GFP	B	pTGF25	GFP	ACE	pTGF66	--	A
pTGF8	GFP	BC	pTGF26	GFP	ADE	pTGF67	--	D
pTGF9	GFP	BE	pTGF27	GFP	BCE	pTGF68	--	C
pTGF10	GFP	BD	pTGF28	GFP	BCDE	pTGF69	--	B
pTGF11	GFP	AB	pTGF29	GFP	ACDE	pTGF82	--	ABD
pTGF13	GFP	CD	pTGF30	GFP	ABCE	pTGF95	--	ABCDE
pTGF14	GFP	AC	pTGF31	GFP	ABDE			
pTGF15	GFP	DE	pTGF32	GFP	ABCD			
pTGF16	GFP	AD	<u>pTGF33</u>	GFP	ABCDE			

For the DNA sequence of pTGF 36, pTGF 53, pTGF 64, pTGF 67, pTGF 82 and pTGF 95, see SEQ ID NOS: 1 and 13 to 17, respectively.

5

Example 2: Isolation of Human Factor IX cDNA

Factor IX cDNA was amplified from human liver cDNA (Clontech) using two primers overlapping the start and termination codon of the factor IX open reading frame resulting in a 1387 bp fragment containing the entire open reading frame. Restriction sites for EcoRI (upstream) and BamHI (downstream) were included at the end of each primer to facilitate cloning. Amplification was performed with Pwo polymerase (Boehringer Mannheim) in 50 ml reaction volume [10 mM Tris HCl pH 8.85, 25 mM KCl, 5 mM (NH₄)₂SO₄, 2 mM MgSO₄] with 30 incubation cycles at 96°C for 1 min, 60°C for 1 min, 72°C for 2 min, followed by a final extension step at 72°C for 10 min.

Reaction products were ligated into the EcoRI- and BamHI-sites of pUC19 and transformed into *E. coli* DH5-a. Positive clones were

selected. Sequences were confirmed by cycle sequencing (Amersham) from both ends with labeled primers (IR-700) and automated analysis on the LiCor sequencing system (MWG, Biotech).

The following primers were used :

5 GGAATTCCGCAAAGGTTATGCAGCGCGTGAACATGATCATGGC
(upstream; SEQ. ID NO: 7)
CGCGGATCCATTAAGTGAGCTTGTCCCCCTTAATCC (downstream;
SEQ. ID NO: 8)

10 **Example 3: Expression and Quantification of the Marker
Protein GFP**

15 Method 1: HeLa cells were transfected by electroporation with
plasmids pTGFG5 or pTGFG20. Transfected cells were harvested and
the cell pellets were homogenized and lysed in a buffer containing
phosphate buffered saline (pH 7.5) and 10 mM PMSF. The
concentration of green fluorescent protein (GFP) in the cell
homogenate was determined by competitive ELISA.

20 For this purpose, GFP was coated in a defined concentration on
microtiter plates. Then, GFP samples were added in the presence of
anti-GFP antibody. After several washing steps a labeled secondary
antibody was added in order to trace the first antibody. The
colorimetric reaction was measured photometrically (extinction).
Generally, the more GFP was added the less antibody was left to bind
25 the coated GFP. Thus, reduction of extinction corresponded to higher
GFP concentration in the sample.

30 A concentration curve of GFP was determined by linear
regression (Figure 11) using bovine serum albumin (BSA) as a
reference. A mean value of 2.4 mg GFP/ml for pTGFG5 (1 PRE) and
5.2 mg GFP/ml for pTGFG20 (3PREs) was found.

Figures 12 a-d show micrographs of HeLa cell cultures transfected with pTGFG5 (Fig. 12 a and b) and pTGFG20 (Fig. 12 c and d), respectively. Figures 12 a and c represent light microscopic views as controls, and Fig. 12 b and d show the corresponding cell patches in the fluorescent mode. Routinely, more than 50% of the cells expressed GFP, indicating very efficient transfection, the presence of only one PRE showing more efficient expression.

Method 2: 293 T cells were transfected with pTGFG 5, 20 and 33 using calcium phosphate method and fluorescence was detected with a fluorimeter (Labsystems, Extinction: 485 nm Emission: 520 nm). In the case of the mock transfection, non GFP-expressing DNA was used. Background indicates the fluorescence of the empty plate (96-well plate, Dynex, Immulon-4). The results are summarized in Fig. 13.

Again the vector with just one PRE (pTGFG5) shows the highest expression.

Example 4: Human Factor IX Quantification by ELISA Assay

HeLa cells were transfected either by electroporation or using liposome reagent DOTAP (Boehringer Mannheim) with plasmids pTGFG36, pTGFG53 and pTGFG64. These plasmids contain the cDNA of human clotting factor IX. Recombinant human factor IX was secreted into the supernatant of the cell culture and quantified using a sandwich ELISA method.

0.11 M sodium citrate and 10 mM PMSF were added in order to prevent degradation of human factor IX. The enzyme-immunological in vitro assay "Asserachrom IX:AG" from Boehringer-Mannheim was used in order to determine the concentration of expressed human

clotting factor IX. The factor IX-standard from Octapharma AG was used as a standard in aqueous solutions of 28 IU/ml.

In six different transfection experiments, in which HeLa cells with plasmids containing human factor IX-cDNA (pTGF36, 53 and 64) were transfected using either electroporation or lipid-transfection reagent (DOTAP, Boehringer Mannheim), a concentration range of 3-25 ng/ml human clotting factor IX was reached.

Example 5: Production and Purification of hPR (A Form)

10

1. Cloning of the human progesterone receptor: The cloning was performed as follows: Total human RNA was isolated from human white blood cells or liver cells using cell lysis in guanidinium hydrochloride buffer and CsCl-density centrifugation.

15

For cloning of the hPR coding sequence, hPR specific cDNA was prepared and used for amplification of the hPR coding sequence in two fragments by PCR.

The following oligonucleotide primers were selected based on the published mRNA sequence (Genbank: NM_000926 and X51730).

20

Oligonucleotides used were obtained from MWG, Ebersberg or Metabion, München. All primers used are listed 5' to 3', bases added to introduce restriction sites are in capital letters and restriction sites used for cloning are underlined.

hPGR-5'-primer: CGA GGA tcc agt cgt cat gac tga gc (SEQ ID NO: 9);

25

hPGR-3'-primer: GCA GAA TT cat tat aaa aac tca aga cct cat aat cct gac (SEQ ID NO: 10);

hPGR-internal primer (Sal I) 1: ctc ctc ggg gtc gac cct gg (SEQ ID NO: 11);

30

hPGR-internal primer (Sal I) 2: cca ggg tcg acc ccg agg ag (SEQ ID NO: 12).

Synthesis of cDNA was performed using 3 µg of total RNA and 200 pmol of the 3'-primer with SuperScript II reverse transcriptase (Gibco BRL). Reaction volume was 50 µl and buffer was used as recommended, supplemented with RNase Inhibitor and 10 mM DTT and 1 mM dNTPs. Before adding the enzyme, samples were heated to 80°C for 10 min, followed by 10 min at 72°C and 10 min at 42°C. SuperScript II RT was added at 42°C and reaction was continued for 15 min at 42°C, 15 min at 50°C and 1 h at 58°C.

10

The cDNA obtained from this synthesis reaction was used to amplify the hPGR coding sequence in two fragments by PCR. One fragment (5') with 5'-primer and internal primer 2 and one fragment (3') with 3' primer and internal primer 1. Reaction setup in 50 µl was: Pwo polymerase (Roche Diagnostics), buffer as supplied by Roche Diagnostics, supplemented with DMSO, 50 pmol of each primer and 0.2 mM dNTPs. Reaction conditions were: 10 min 96°C followed by 35 cycles of 1 min 96°C, 2 min at 59°C, 2 min 72°C and a final extension step at 72°C for 10 min.

15

PCR-products were purified by gel electrophoresis and digested with Sal I. The BamHI and Hind III sites introduced in the primer were not used to avoid cutting at two internal restriction sites of the hPR coding sequence. Both fragments were ligated into pBluescript SK+ vector 20 cut with EcoRV through blunt end ligation into the vector and sticky end ligation through the internal Sal I site. Vectors containing the appropriate insert were identified by mini-prep, restriction digest and sequencing. The obtained vector was designated pTGHPR1.

2. Production of hPR (A-form): Initially, the gene for hPR-B inclusive its 3'-UTR was cut out from pTGH PR1 and cloned in frame in the multiple cloning site of the expression plasmid pFASTBAC HTc (BAC-to-BAC Baculovirus Expression System, Life Technologies). This 5 resulted in an expression cassette of a N-terminally histidine-tagged version of hPR-B under expression control of the viral polyhedrin promotor as shown below. A rTEV protease cleavage site is located between the six histidine residues and the initial methionine of the hPR-B reading frame, which allows removal of the histidine residues 10 from the expressed protein. The N-terminal region of the expression cassettes is shown below.

15 **MSYYHHHHHHDYDIPPTENLYFQ**GAMGIRNST-hPR-gen**
6 x His _____
spacer _____
rTEV cleavage site

Amino acids are presented in the single letter code. The cleavage site of the rTEV protease is represented by **

20 In order to generate the expression cassette for the truncated hPR-A form, the DNA sequence encoding for the amino acids between Met 1 and Met 165 of the hPR-B form was removed using a PCR-based strategy. Two primer pairs were designed which allowed amplification 25 of either a DNA fragment just downstream of the start AUG of the hPR-B gene and a DNA-fragment just upstream of the AUG coding for Met 165, respectively. In a subsequent PCR reaction these two DNA fragments were annealed to each other at their homologous 3'-ends, and amplified using the outermost amplification primers. The resulting 30 DNA-fragment was digested by EcoRI and Mlu I and the cleavage product was exchanged against the corresponding fragment of the

hPR-B expression cassette in the pFASTBAC HTc vector. Thereby the reading frame coding for an N-terminal histidine tagged version of the hPR-A polypeptide (94kDa) was restored.

This 6×His-tag was utilised for affinity purification of the protein by immobilized cobalt²⁺ affinity chromatography on a TALON® resin (Clontech). The procedure, following the method of Boonyaratankornkit et al. Mol. Cell. Biol.18, 4471 (1998), was as follows (all steps were carried out at 0 to 8°C):

Sf9 cells were cultivated in monolayer culture in serum free SF900 medium. Viral infection of the cells was done at a multiplicity of infection (MOI) of 5-8.

The harvesting was done 48 hours after infection with baculovirus containing the hPR expression cassette and lysed mechanically by homogenising in buffer A containing 20 mM Tris-Cl pH 8.0, 350 mM NaCl, 10 mM imidazol, 5% glycerol and a cocktail of proteinase inhibitors (Complete™ EDTA-free, Roche Diagnostics, Penzberg, Germany). After a 10 min centrifugation at 10000 × g, supernatant originating from 10⁸ cells was incubated for 1 h with 0,5 ml settled TALON® resin equilibrated in buffer A. TALON® was washed with 20 volumes of buffer A. hPR-A was eluted with 10 Vol buffer B, containing all ingredients of buffer A, but 100 mM imidazol. The eluate was concentrated 50-fold and dialysed against 100 volumes buffer C (PBS + 100 nM progesteron) by centrifugal ultrafiltration at a molecular exclusion size of 10 kDa (Centricon Plus-20 PL-10, Millipore, Eschborn, Germany).

3. Determination of identity, purity and yield of hPR-A: Purity and yield of the product were determined by application on denaturing reducing polyacrylamid- gelectrophoresis according to Laemmli, U. et al., Nature 227, 680-685 (1970) and subsequent staining with

coomassie[®] blue R250. By this one-step procedure hPR-A was enriched to a final specific hPR content of 0.2 - 0.5 mg hPR/mg protein. As depicted in Figure 15, lane A, the final preparation consisted predominantly of two distinct protein species displaying apparent molecular masses of 94 and 74 kDa (Fig. 15, arrows).

Yield was estimated by parallel separation of standardised protein preparations. Data taken from a set of three separate experiments hint at a typical yield of 30 µg enriched hPR A-receptor per 10^8 cells.

Identity of hPR was determined by immunodetection of the product transferred to nitrocellulose by western blotting with mouse monoclonal antibodies directed against recombinant hPR (PR Ab-1, Oncogene, Cambridge, MA, USA).

The final product was transferred to nitrocellulose BA-83 and immunostained as described above. As presented in Figure 15, lane C, three major protein bands were detected, including the two dominant protein species described above. The smaller sized bands may display copurified proteolytic fragments of hPR.

Intracellular GFP from adherent cells was detected by a fluorimeter after media was taken off and PBS (colourless) was added. The results are summarized in Fig. 13.

Example 6: Clotting Activity of Human Clotting Factor IX from Transfected 293 T Cells

25

A concentration range of 55 - 95 ng/ml human clotting factor IX has been reached by transfection of 293 T-cells with plasmids containing human factor IX-cDNA (pTGFG 36, 53, 64 and 2) in 11 different experiments using ELISA (Example 4).

30

Clotting activity was determined with a partial thromboplastin time

assay using Cephalin (phosphatidyl ethanolamine) activation with a manual coagulation instrument (ML-2, Instrumentation Laboratories). For the study, 100 µl undiluted supernatant from transfected 293 T-cells, 100 µl deficiency plasma (Progen) and 100 µl Cephalin (Instrumentation Laboratories) were incubated for 5 minutes at 37°C. Coagulation was started by adding 100 µl CaCl₂. Sample coagulation time was compared to normal plasma.

Number of cells [/ml]	Factor IX-concentration [ng/ml]	Clotting time [s]
2,1 x 10 ⁵	36	45
8,7 x 10 ⁵	20	79

10 Normal plasma: 37 – 39 s
 Factor IX deficient plasma: 137 – 140 s

Example 7: Analysis of an Additive Effect of Human Clotting Factor IX on the Clotting Time of Mice Blood

15 1. Clotting time: Clotting activity was determined with a partial thromboplastin time assay using Cephalin (phosphatidyl ethanolamine) activation with a manual coagulation instrument (KC 4 A, Amelung).

20 For the study, 5 µl mouse blood, 20 µl deficiency plasma (Progen) and 100 µl physiological NaCl and 100 µl DaPPTin (Progen) were incubated for 2 minutes at 37°C. Coagulation was started by adding 100 µl CaCl₂.

25 To analyse the additive effect, human clotting factor IX (housestandard, Octapharma) was added to the mouse blood and diluted 1:10 within the system. As it is shown in Figure 15, the additive effect of human clotting factor IX on clotting activity can be

detected up to a limit concentration of 0,07 mIU hFIX/ml (= 31,5 ng/ml).

55 **2. ELISA:** The addition of human clotting factor IX to the mouse blood was monitored by ELISA as described in Example 4. Citrate plasma was made out of mouse blood and human clotting factor IX was added in different concentrations.

No.	Description	Concentration [mIU/ml] hFIX added	Extinction at 405 nm [-]
1.	Mouse Citrate Plasma	7	0,204
2.	Mouse Citrate Plasma	2	0,130
3.	Mouse Citrate Plasma	-	0,099
4.	Control: 1.+2. Antibody without antigen	-	0,096
5.	Control: 1. Antibody without antigen	-	0,072
6.	Control: 2. Antibody without antigen	-	0,085
7.	Substrate (ABTS)	-	0,072

10 Mouse plasma without the addition of human clotting factor IX showed an extinction of 0,099 at 405 nm background. When added human factor IX in a concentration of 2 mIU/ml (= 9 ng/ml human factor IX) the detection limit is reached. It can be deduced that the antihuman factor IX antibodies used in the ELISA are not cross-reactive with 15 mouse coagulation factor IX.

Example 8: Cloning and Activity Testing of the Human Progesterone Receptor (hPR)

2. Activity Testing: The human progesterone receptor encoded in plasmid pTGHPR1 (s. Example 8.1 above) was tested for its physiological activity. In a functional form and after activation with a progestin like R5020 the receptor should be able to induce the expression of luciferase from a Mouse Mammary Tumor Virus (MTV) promoter.

5 To test this 293T cells were grown in phenol red-free DMEM supplemented with 10% charcoal-filtrated fetal calf serum and with or without 10 nM of R5020 (NEN) in 6 well plates. Transfections were performed by the calcium phosphate method using 2 µg of a pSG-hPR1 construct and pMTV-luc (Hollenberg et al., 1985, Cell 55, p899-906) per well. One day after transfection the cells were washed in PBS and the luciferase expression assayed with the Berthold luciferase kit according to the manufacturer's directions in a fluorimeter (Labsystems). The controls were as follows: R5020 was omitted (PR+MTV) and both plasmids alone were transfected with (PR+R5020, 15 MTV+R5020) and without R5020 (PR, MTV). As positive control a plasmid with a CMV-driven luciferase gene was transfected (pCMV-luc).

20

25 As can be seen in Figure 19, there is a clear induction of luciferase expression when all the necessary elements are present, that is human progesterone receptor, progestin R5020 and the MTV-driven luciferase gene (PR+MTV+R5020). The error bars give the standard deviation of a threefold experiment, the readout is relative light units (RLU).

Example 9: Oral Gene Transfer in *in vivo* Animal Experiment

Purpose of experiment: The object of this pilot study is to prove oral gene transfer in an *in vivo* animal experiment. Successful gene transfer is established by coagulation measurement: an additive effect of expressed human factor IX on the coagulation time of healthy murine whole blood is expected. The presence of expression of human factor IX in mouse blood is quantitated by ELISA.

Animals: The animals employed are 35 male C57BL/6J mice from Iffa Credo, France, with an initial age of 9 weeks and a weight of 23-33 g. The mice are kept in groups of 7 animals each in conventional test animal cages with wooden chips in the Institut für Experimentelle Onkologie und Therapieforschung der Technischen Universität München.

15 The animals are fed ad libitum with "Altrum Ratten und Mäuse Haltung" and are given tap water, also ad libitum.

The test animal cages are kept at an ambient temperature of 19-24°C and a humidity of 55-5%. The room is additionally provided with an automatic light supply which maintains a 12 hours rhythm.

20 The test animals are supervised by specialized staff.

Mixture of substances:

Group	Hormone	Hormone receptor	Plasmid	Aqua dest.	Route of administration
1. -	-	-	-	-	-
2. -	100 µl	-	10 µg	-	oral
3. -	-	-	10 µg	100 µl	oral
4. -	-	-	10 µg	50 µl	i.m.
5. -	100 µl	4.35 µg	10 µg	-	oral

Course of experiment: The 35 mice were divided into 5 groups of 7 mice each. One group serves as a control, the second group was daily administered a total of 100 μ l of hormone and plasmid via the gastro-intestinal tract orally with an esophageal sound, the third group was daily administered a total of 100 μ l of plasmid with aqua dest. orally with an esophageal sound, the fourth group was administered a total of 50 μ l of plasmid with aqua dest. i.m. into the musculus quadriceps femoris, the fifth group was daily administered a total of 100 μ l of hormone, hormone receptor and plasmid orally with an esophageal sound.

About 2-3 hours before the manipulation, the mice were prewarmed under a red light. Immediately before, during and after the manipulation, the mice were examined and supervised by a veterinarian.

25 Blood sampling from the mice was performed daily from the caudal artery of animals slightly sedated by inhalation anesthesia. For this purpose the artery was punctured with a disposable injection cannula (0.90 x 40 mm). Whole blood welling out of the puncture site (5 μ l of blood) was immediately collected with an Eppendorf pipette.

30 Without further delay, the blood coagulation time in seconds was

determined using an Amelung-Koagulometer KC 4A by means of an aPTT assay (activated partial thromboplastin time). The blood coagulation analysis was always performed by the same person. Immediately after the blood sampling, the bleeding was stopped by 5 compression.

Sedation of the mice was achieved by inhalation anesthesia (active substance: isoflurane: Forene, Abbott GmbH, 65205 Wiesbaden, Western Germany) in a whole body chamber.

The daily manipulation was performed through an overall period of 7 10 days. This was followed by a day (day 8 of experiment) without any manipulation, and at day 9 of experiment, again 5 µl of whole blood was withdrawn from the ventral caudal artery under anesthesia, and the coagulation time established as described above. Further, 0.5- 15 0.75 ml of whole blood was collected intracardially using U-40 insulin syringes (Mikro-Fine 12.4 mm) filled with 50-75 µl of sodium citrate (3.1%), transferred into Eppendorf cuvettes, and about 100 µl of whole blood with citrate was reserved for PCR examination and stored in a cool environment. The remaining citrate blood was centrifuged for 10 min using a centrifuge 6000 rpm, 4°C, at 5000 rpm, and the plasma 20 was recovered for the ELISA determination of the factor IX concentration.

Then, the animals were sacrificed using 0.5 ml Narkoren i.p. Immediately after the sacrificing, the animal bodies were dissected. The following organs were removed from the mice for an 25 immunohistochemical examination: brain, spleen, liver, kidneys, testes, lungs, m. quadriceps femoris, heart, appendix; and frozen at -80°C.

Deviation from the scheduled experimental course: Due to the poor general condition of the mice in the course of the long-term 30 administration series, the administration had to be interrupted at days

3 (except one mouse) and 5 for test group 2 (hormone and plasmid), at days 3 and 5 for group 5 (hormone, hormone receptor and plasmid), and two mice were additionally spared the administration of the reagents at days 2 and 7 of the experiment.

5 The poor general condition is accounted for by the hypnotic effect of the hormone progesterone. It causes the mice to sleep for about 24 hours without eating and drinking. This again has an adverse effect on the water balance of the mice, resulting in exsiccotic phenomena and apathic behavior. Therefore, the mice were prophylactically treated with
10 a subcutaneous administration of 1 ml of 5% glucose solution (Delta Pharma GmbH, 72793 Pfullingen) and 1 ml of Ringer solution (Delta Pharma GmbH, 72793 Pfullingen) when the hormone was administered orally. Among the group which was orally administered hormone, hormone receptor and plasmid, two mice died at days 3 and 6,
15 respectively; they were dissected.

Among the group which was orally administered hormone with plasmid, one mouse was found dead in its cage on day 8 of the experiment; it was also dissected.

20 The results are summarized in Figures 17 and 18. The statistical evaluations were performed according to the generalized linear model with repeated measurements (MANOVA with repeated measurements). In none of the test groups a non-linear course was observed. Therefore, the course was calculated by a simple representation of the linear increase or decrease, namely initial value minus final value per
25 mouse. The particularly interesting difference between the control and the group "plasmid in the hormone with hormone receptor" (group 5) was examined using a T test for independent random samples.

Figure 17 shows the mean values of the calculated differences: In the control, for example, this difference was about 50 seconds. The
30 vertical lines show plus and minus one standard deviation from these

values. The T test is based both on the differences between the mean values and on the degree of overlapping which can be seen from these lines: The larger the overlapping, the less is the significance of the mean value differences. Thus, the groups "control" and "plasmid and water i.m." (groups 1 and 5, respectively) are distinguished in a purely numerical way in the mean value, but the degree of overlapping is so high that these groups are not significantly different.

The only significant difference was between group 1 and 5: The decrease of the latter is significantly higher than that of the control ($T = -2.357$; d.f. = 12; $p < 0.05$).

The following Tables contain the concluding statistics and the results of the statistical tests (T test) performed on the differences between the mean values obtained in the course of the test:

15

Group statistics

ADMIN		N	mean value	standard deviation	standard error of the mean value
DIF	control	7	47.3857	58.9946	22.2978
	Hormone, hormone receptor and plasmid orally	7	114.7571	47.3300	17.8891

Test for independent random samples

	Levene test for equal variance		T test for equal mean values							
	F	Significance	T	df	sig. (2-sided)	mean difference	standard error of difference	95% confidence interval of difference		
								lower	upper	
DIF	variances are equal	0.026	0.874	-2.357	12	0.036	-67.3714	28.5869	-129.6570	-5.0858
	Variances are not equal			-2.357	11.461	0.037	-67.3714	28.5869	-129.9833	-4.7596

The human F IX was also detectable in the treated mice of the "hormone-hormone reception and plasmid orally group using an Elisa
5. as described in Example 4.

Claims

1. Use of a nucleic acid construct comprising at least one hormone responsive element (HRE) and a transgene for preparing an agent for gene transfer.
- 5
2. The use of claim 1, wherein the at least one HRE is functionally linked to the transgene or not.
- 10
3. The use of claim 1 or 2, wherein the transgene is selected from the group consisting of genes encoding a blood clotting factor, hormone genes, hormone receptor genes, growth factors, enzyme genes, genes encoding cytokines or lymphokines, genes encoding inhibitor substances, genes encoding substances that function as drugs or vaccines, and antisense sequences.
- 15
4. The use of claim 3, wherein the transgene is a gene encoding a blood clotting factor and the agent is suitable for treating hemophilia.
- 20
5. The use of claim 4, wherein the human blood clotting factor is selected from the group consisting of factor VIII, factor IX, and von Willebrand Factor (vWF).
- 25
6. The use of claims 1 to 5, wherein the nucleic acid construct comprises 1 to 20, preferably 3 to 10 HRE(s).
7. The use of claim 1 to 5, wherein the at least one HRE is a steroid responsive element, preferably a progesterone responsive element (PRE).

8. The use of claim 5, wherein the HRE is a PRE and the blood clotting factor is factor IX, preferably the factor IX has a nucleotide sequence of 689 to 2071 of SEQ ID NO: 1.
- 5 9. The use of claim 5, wherein the HRE is a PRE and the blood clotting factor is factor VIII.
10. The use of claim 7 to 9, wherein the PRE has the double stranded DNA sequence comprised of the DNA sequences of SEQ ID NOs: 3 and 4.
- 15 11. The use of claims 1 to 10, wherein the construct further comprises functional DNA sequences selected from the group consisting of promoter sequences, enhancer sequences, silencer sequences, origin of replication sequences, integrational sequences, marker genes and switch sequences.
- 20 12. The use of claim 11, wherein the construct further comprises a tissue-specific promoter, preferably an α -antitrypsin promoter.
13. The use according to any one of claims 1 to 12, wherein the agent further comprises a hormone-hormone receptor complex, preferably a steroid-steroid receptor complex.
- 25 14. The use of claim 13, wherein the molar ratio of HRE within the nucleic acid construct to hormone receptor is from 1:1 to 1:10, preferably 1:2 to 1:5, and/or the molar ratio of hormone to hormone receptor is at least 1000:1, preferably at least 10000:1.
- 30 15. The use of claim 13 or 14, wherein the receptor is a progesterone

receptor and the steroid is progesterone or a progesterone derivative.

16. The use of claim 15, wherein the progesterone is natural micronized progesterone solubilized in a lipophilic matrix system and/or the progesterone receptor is hPR-A, hPR-B or comprises the nucleotide sequence of 557 to 933 SEQ ID NO: 9.

17. A nucleic acid construct comprising at least one HRE and a transgene, wherein one of said at least one HREs is not functionally linked to the transgene.

18. The nucleic acid construct of claim 17, which is as defined in claims 3 to 12.

19. A vector comprising the nucleic acid construct of claim 17 or 18.

20. A transformed cell or transgenic organism comprising the nucleic acid construct as defined in claims 17 or 18 or the vector as defined in claim 19.

21. A composition of matter comprising a nucleic acid construct comprising at least one HRE and a transgene as defined in claim 17 or 18 and/or a vector as defined in claim 19, said at least one HRE being coupled to a hormone-hormone receptor complex.

22. The composition of matter of claim 21, wherein the hormone-hormone receptor complex is as defined in claims 13 to 16.

23. The composition of matter of claim 21, wherein the transgene is a gene encoding a blood clotting factor.

24. The composition of matter of claim 21 wherein the blood clotting factor is factor IX.

5 25. The composition of matter of claim 21 wherein the blood clotting factor is factor VIII.

10 26. A method for preparing the composition of matter as defined in claim 21, which method comprises admixing the nucleic acid construct with the hormone receptor and the hormone.

15 27. A pharmaceutical composition comprising the nucleic acid construct of claim 17 or 18, the vector of claim 19, and/or the composition of matter of claim 21 to 25.

28. The pharmaceutical composition of claim 27, which is suitable for gene transfer, preferably for treating hemophilia.

20 29. A method for gene transfer which comprises administering the agent as defined in claims 1 to 16, or the composition of matter as defined in claims 21 to 25 to an organism or to a cellular system.

25 30. A method for delivering into an organism or into a cellular system a nucleic acid encoding a transgene to be expressed in the cells of the organism or the cells of the cellular system, which method comprises administering an agent as defined in claims 1 to 16 or composition of matter as defined in claims 21 to 25 to the organism or to the cellular system so that the hormone in the composition interacts with the cell membrane and therewith enhances diffusion and transport of the

nucleic acid that is coupled to the hormone-hormone receptor complex across the membrane and into the cell.

31. The method of claim 30, wherein a nucleic acid encoding human factor VIII or factor IX is delivered into the cell.
32. A method of treating blood clotting disorders comprising administering a therapeutically effective amount of the composition of matter of claim 23 to an organism or to a cellular system.
- 10 33. A method of treating hemophilia B, comprising administering a therapeutically effective amount of the composition of matter of claim 24 to an organism or to a cellular system.
- 15 34. A method of treating hemophilia A, comprising administering a therapeutically effective amount of the composition of matter of claim 25 to an organism or to a cellular system.
35. Use of a steroid hormone for preparing an agent for gene transfer.
- 20 36. The use of claim 35, wherein the steroid hormone is a natural micronized steroid hormone, preferably natural micronized progesterone.
- 25 37. The use of claim 36, wherein the natural micronized steroid hormone is solubilized in a lipophilic matrix system.
38. A method for gene transfer which comprises administering a nucleic acid construct to an organism or to a cellular system, wherein

52

the nucleic acid construct contains a transgene and is encapsulated in a steroid hormone.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7





Fig. 8



9/22
Fig. 9

CGCGTTGACATTGATTATTGACTAGTTATTAAATAGTAATCAATTACGGGGTCATTAGTTCAAGCCCCATATATGGAGTT
 CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCCCAACGACCCCCGCCATTGACGTCAATAATGACGTA
 TGTCCCCATAGTAAACGCCAATAGGGACTTCCATTGACGTCAATGGGGAGTATTACGGTAAACTGCCCACTTGGCAG
 TACATCAAGTGTATCATATGCCAAGTACGGCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAG
 TACATGACCTTATGGACTTCCATTGGCAGTACATCTACGTATTAGTCATCGCTATTACATGGTATGCGGTTTG
 GCAGTACATCAATGGCGTGGATAGCGGTTGACTCACGGGATTTCAGTCCACCCATTGACGTCAATGGGAGTT
 TGTGGCACCAAAATCAACGGACTTCCAAAATGCTAACAACTCCGCCATTGACGCAATGGCGGTAGGCGT
 GTACGGGGAGGCTATATAAGCAGAGCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAAAC
 GACTCACTATAGGGAGACCCAAAGCTTGCAATTCCGAAAGGTTATGCAGCGGTGAACATGATCATGGCAGAATC
 ACCAGGCCTCATCACCCTGCCTTCTGGATATCTACTCAGTGTGAATGTACAGTTCTGATCATGAAAAGCCA
 AAAAAATTCTGAATCGGCAAAGAGGTATAATTCAAGGTTAAATTGGAAGAGTTGTCAGGGAACCTTGAGAGAGAATGT
 ATGGAAGAAAAGTGTAGTTGAAGAAGCAGGAGTTGAAAACACTGAAAGAACAACTGAATTGGAAGCAGTA
 TGTGATGGAGATCAGTGTGAGTCCAATCCATGTTAAATGGCGCAGTGCAAGGATGACATTAATTCTATGAATGTT
 GGTGCCCCCTGGATTGAAAGGAAAGAATGTAATTAGATGTAACATGTAACATTAAGAATGGCAGATGCGAGCAGTT
 TGTAAAATAGTGTGATAACAAGGTGTTGCTCTGTACTGAGGGATATGACTTGAGAAAACCAGAAGTCTGTGA
 ACCAGCAGTGCCATTCCATGTGGAGAGTTGTTCAACAAACTCTAACGTCACCGTGCTGAGACTGTTTCTG
 ATGTGGACTATGTAATTCTACTGAAAGCATTGATAACATCACTCAAGCACCAATCTTAATGACTTC
 ACTCGGGTTGTTGGAGAAGATGCCAAACCAGGTCAATTCCCTGGCAGGTTGTAATGGTAAGTTGATGCAATT
 CTGTTGGAGGCTCATCGTTAATGAAAATGGATTGTAACTGCTGCCACTGTTGAAACTGGTGTAAAATTACAGTTG
 TCGCAGGTGAACATAATTGAGGAGACAGAACATACAGAGCAAAGGCAAATGTGATTGAAATTCTCACCACAAAC
 TACAATCAGCTTAAATGAAACCATGACATTGCCCTCTGGAACTGGCACAAACCTAGTCTAACAGCTACGT
 TACACCTATTGCTGACAAGGAATACAGAACATCTCCAAATTGGATCTGGCTATGTAAGTGGCTGGGAA
 GAGTCTTCCACAAAGGGAGATCAGCTTAGTTCTCAGTACCTTAGGTTCTGAGGACTTCACTGTTGACCGAGCCACATGTC
 TCTACAAAGTTCACCATCTATAACACATGTTCTGCTGGCTTCCATGAAGGAGGTTAGAGATTGTCAGGGAGATAG
 TGGGGACCCATGTTACTGAAAGGGACAGTTCTAACGGATTATTAGCTGGGTGAAGAGTGTGCAATGA
 AAGGCAAATATGGAATATACCAAGGTATCCGGTATGTAACGGAAACAGCTAACCTAATGGGAT
 CGGTGAGCGGCCGCACTACTAGAGGATCTTGTGAAGGAACCTTACTCTGTTGACATAATTGGACAAACTA
 CCTACAGAGATTAAAGCTCTAACGTTAAATTAAATTGTTAAGTGTATAATGTTAACACTGATTCTAACATTGTTG
 TGTATTAGATTCAACCTATGAACTGATGAATGGGAGCAGTGGTGAATGCCATTATGAGGAAAACCTGTTGCT
 CAGAAGGAAATGCCATCTAGTGTGAGGCTACTGCTGACTCTAACATTCTACTCCTCCAAAAAGAAGGAAAGGTA
 GAAGACCCCAAGGACTTCCCTCAGAATTGCTAAAGTTGAGTCATGCTGTGTTAGTAATAGAATCTGCTTGCTT
 TGCTATTACACCACAAAGGAAAAGCTGCACTGCTATAACAGAAAATTGAAATATTCTGTAACCTTATAAGTA
 GGCATAACAGTTATAATCATAACACTGTTTCTTACTCCACACAGGCATAGAGTGTCTGCTATTAAACTATGCT
 CAAAATTGTCACCTTCTAGTTAAAGGGTTAATAAGGAATTGATGATAGTGCCTTGACTAGAGA
 TCATAATCAGCCATACCACATTGTAAGGGTTACTTGCTTAAACCTCCACACCTCCCCCTGAAACCTGAAACAT
 AAAATGAATGCAATTGTTGTTAACTGTTATTGCAAGCTTATAATGGTTACAAATAAGCAATAGCATCACAAATT
 CACAAATAAGCATTCTTCACTGCATTCTAGTGTGGTTGTCACACTCATCAATGTATCTTATCATGTC
 CGGACTCCTCTAGAGCAATTAACTACTGCCCTGCTTACAACAGCTGCTGACTGGGAAACCTGGCTTACCAA
 CTTAATCGCCCTGCAACATCCCCCTTCGCGCTGCTGCTGTAATAGCGAAGAGGCCGACCGATGCCCTCCCAAACA
 GTTGCCTGAGCCTGAATGGCGAATGGCGCTGATGGCTATTCTCCTACGCTATGTCGGTATTTCACACCGCATAT
 GGTGCACTCTCAGTACAATCTGCTCTGATGCCGCTAGTTAACGGCAGGCCGACACCCGCTGACCGGCC
 TGACGGGCTTGTCTGCTCCGGCATCCGTTACAGACAAGCTGTCAGGGCTCTGGGAGCTGCTATGTCAGAGGTTTC
 ACCGTCATCAGGAAACGCCGAGACGAAAGGGGGTACCGAGCTCGTAGCTAGAACATCATGTTCTGGATATCAGCT
 TCGTAGCTAGAACATCATGTTCTGGTACCCCTCGTAGCTGATACGCTTATTGTTATAGGTTATGTCATGATAATAATGGTT
 TCTTAGACGTCAGGTGGCACTTCTGGGAAATGTGCGGAAACCCCTATTGTTATTCTAACATACATTCAAATAT
 GTATCCGCTCATGAGACAATAACCCGATGAAATGCTCAATAATATTGAAAAGGAAGAGTATGAGTATTCAACATTCC
 GTGTCGCCATTCCCTTTGCGGCATTGCTCTGTTTGCTCACCCAGAAACGCTGGTAAAGTAAAGAT
 GCTGAAAGATCAGTGGGTGACGAGTGGTTACATGAACTGGATCTAACAGCGGTAAAGATCTGAGAGTTGCCCC
 CGAAGAACGTTTCAATGATGAGCAGTTAAAGGTTCTGCTATGTCGGCTATTATCCGTATTGACGCCGGCAAG
 AGCAACTCGGTGCCGCATACACTATTCTCAGAACGACTTGGTGAAGTACTCACCAGTCACAGAAAAGCATCTACGGAT
 GGCATGACAGTAAGAGAATTATGCACTGCTGCCATAACCATGAGTGATAACACTGCGGCCACTTACTCTGACAAACGAT
 CGGAGGACCGAAGGAGCTAACCGTTTTGCAACATGGGGATCATGTAACCTGCTTGATGCTGGGAAACCGGAGC
 TGAATGAAGCCATACCAACGACGAGCGTGAACACCACGATGCCGTAGCAATGGCAACACGCTTGC
 CGCAACTACTTACTCTAGCTCCGCCAACAAATTAGACTGGATGGAGGCGATAAAGGTTGAGGACCACTCTGCG
 CTGGCCCTTCCGCTGGCTGTTATTGCTGATAATCTGGAGCCGGTGGCTGAGCTGGCTGAGGAGCTTGC
 TGGGGCCAGATGGTAAGCCCTCCGTTACGCTAGTTATTCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGA
 CAGATCCTGAGGATAGGTGCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTACTCATATAACTTTAGATTGA
 TTTAAAATTCTATTAAATTAAAGGATCTAGGTGAAGGATCCTTGTATAATCTCATGACCAAAACCTTAACTG
 AGTTTCTGTTCCACTGAGCGTCAGACCCGTTAGAAAAGGATCAAAGGATCTTCTGAGATCCTTCTGCGCTAATC
 TGCTGCTTGCACAAACAAAAACACCAGCTTACAGCGGTGGTTGCTGCGGATCAAGAGCTACCAACTCTTCCGAA
 GGTAACCTGGCTTCACTGAGCGCAGATACCAAAACTGTTCTCTAGTGTAGCCGTTAGTTAGGCCACCACTTCAGAAC
 CTGTCAGGCCCTACATACCTCGCTGCTAACCTGTTACAGTGGCTGCTGCCAGTGGCGATAAGTC
 GTGCTTACCGCAGGCTGAGGAGTACGGGATAAGGCGCAGCGGTGGCTGAACGGGGGTTGTC
 GACACAGCCAGCTTACAGCGTGTGAGCTGAGAAAGCGCCACGCCAGCTTCCCGAAGGGAGAAAGG

10/22

Fig. 9 (continued)

CGGACAGGTATCCGTAAGCGGCAGGGCGGAACAGGAGAGCGCAGGAGGGAGCTCCAGGGGAAACGCCTGGTATCTT
TATAGTCTGTCGGTTTGCACCTCTGACTTGAGCGTCGATTTGTGATGCTCGTCAGGGGGCGGAGCCTATGGAA
AAACGCCAGCAACCGCGCCCTTTACGGTCTGGCCTTTGCTGGCCTTGCTCACATGTTCTTCCTGCCTTATCCC
CTGATTCTGTGGATAACCGTATTACCGCTTTGAGTGAGCTGATACCGCTCGCCGAGCCGAACGACCGAGCGCAGCGAG
TCAGTGAGCGAGGAAGCGGAAGAGCGCCAAATACGCAAACCGCTCTCCCAGCGCGTTGGCCGATTCAATTAGCAGCTG
GCACGACAGGTTCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAATGTGAGTTAGCTCACTCATTAGGCACCCC
AGGCTTACACTTATGCTCCGGCTCGTATGTTGAGCTAACAAATTACACAGGAAACAGCTAT
GACCATGATTACGCCAAGCTCTAGAGCTCTAGAGCTAGAGAGCTTGCAATGCCCTGCAGGTG

11/22
Fig. 10

Met Gln Arg Val Asn Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr
 1 5 10 15

Ile Cys Leu Leu Gly Tyr Leu Leu Ser Ala Glu Cys Thr Val Phe Leu
 20 25 30

Asp His Glu Asn Ala Asn Lys Ile Leu Asn Arg Pro Lys Arg Tyr Asn
 35 40 45

Ser Gly Lys Leu Glu Glu Phe Val Gln Gly Asn Leu Glu Arg Glu Cys
 50 55 60

Met Glu Glu Lys Cys Ser Phe Glu Glu Ala Arg Glu Val Phe Glu Asn
 65 70 75 80

Thr Glu Arg Thr Thr Glu Phe Trp Lys Gln Tyr Val Asp Gly Asp Gln
 85 90 95

Cys Glu Ser Asn Pro Cys Leu Asn Gly Gly Ser Cys Lys Asp Asp Ile
 100 105 110

Asn Ser Tyr Glu Cys Trp Cys Pro Phe Gly Phe Glu Gly Lys Asn Cys
 115 120 125

Glu Leu Asp Val Thr Cys Asn Ile Lys Asn Gly Arg Cys Glu Gln Phe
 130 135 140

Cys Lys Asn Ser Ala Asp Asn Lys Val Val Cys Ser Cys Thr Glu Gly
 145 150 155 160

Tyr Arg Leu Ala Glu Asn Gln Lys Ser Cys Glu Pro Ala Val Pro Phe
 165 170 175

Pro Cys Gly Arg Val Ser Val Ser Gln Thr Ser Lys Leu Thr Arg Ala
 180 185 190

Glu Thr Val Phe Pro Asp Val Asp Tyr Val Asn Ser Thr Glu Ala Glu
 195 200 205

Thr Ile Leu Asp Asn Ile Thr Gln Ser Thr Gln Ser Phe Asn Asp Phe
 210 215 220

Thr Arg Val Val Gly Gly Glu Asp Ala Lys Pro Gly Gln Phe Pro Trp
 225 230 235 240

Gln Val Val Leu Asn Gly Lys Val Asp Ala Phe Cys Gly Gly Ser Ile
 245 250 255

Val Asn Glu Lys Trp Ile Val Thr Ala Ala His Cys Val Glu Thr Gly
 260 265 270

Val Lys Ile Thr Val Val Ala Gly Glu His Asn Ile Glu Glu Thr Glu
 275 280 285

His Thr Glu Gln Lys Arg Asn Val Ile Arg Ile Ile Pro His His Asn
 290 295 300

12/22

Fig. 10 (continued)

Tyr Asn Ala Ala Ile Asn Lys Tyr Asn His Asp Ile Ala Leu Leu Glu
305 310 315 320

Leu Asp Glu Pro Leu Val Leu Asn Ser Tyr Val Thr Pro Ile Cys Ile
325 330 335

Ala Asp Lys Glu Tyr Thr Asn Ile Phe Leu Lys Phe Gly Ser Gly Tyr
340 345 350

Val Ser Gly Trp Gly Arg Val Phe His Lys Gly Arg Ser Ala Leu Val
355 360 365

Leu Gln Tyr Leu Arg Val Pro Leu Val Asp Arg Ala Thr Cys Leu Arg
370 375 380


Ser Thr Lys Phe Thr Ile Tyr Asn Asn Met Phe Cys Ala Gly Phe His
385 390 395 400

Glu Gly Gly Arg Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro His Val
405 410 415

Thr Glu Val Glu Gly Thr Ser Phe Leu Thr Gly Ile Ile Ser Trp Gly
420 425 430

Glu Glu Cys Ala Met Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Ser
435 440 445

Arg Tyr Val Asn Trp Ile Lys Glu Lys Thr Lys Leu Thr
450 455 460

13/22
Fig. 11

SUBSTITUTE SHEET (RULE 26)




Fig. 12a



Fig 12 b




Fig 12 c




Fig 12 d

16/22
Fig. 13

Detection of GFP expressed from Theragene-vectors (n=16)






Fig. 14

Additive effect of human factor IX on clotting time of mouse blood




SUBSTITUTE SHEET (RULE 26)

Fig. 15



SUBSTITUTE SHEET (RULE 26)

Fig. 16






Fig. 17





Fig. 18

Fig. 19



21/22

1 MTELKAKGPR A_{PI}IVAGGPPS PEVGSPLLCR PAAGPFPGSQ TSDTLPEVSA IPISLDGLLF
61 PRPCQGQDPS DEKTQDQQSL SDVEGAYSRA EATRGAGGSS SSPPEKDSDL LSVLDTLLA
121 PSGPGQSQPS PPACEVTSSW CLFGPELPED PPAAPATQRV LSPLMSRSGC KWGDSSGTAAC
181 AHKVLPRGLS PARQLLPAS ESPHWSGAPV KPSPQAAVE VEEEEDGSESE ESAGPLLKGK
241 PRALGGAAAG GGAAAVPPGA AAGGVALVPK EDSRFSAPRV ALVEQDAPMA FGRSPPLATT
301 MDFIHVPILP LNHALLAART RQLEDESYD GGAGAAASAF A PPRSSPCASS TPVAVGDFPD
361 CAYPPDAEPK DDAYPLYSDF QPPALKIKEE EEEGAEASARS PRSYLVAGAN PAAFPDFPLG
421 PPPPLPPRAT PSRPGEAAVT AAPASAVSS ASSSGSTLEC ILYKAEGAPP QQGPFAAPPC
481 KAPGASGCLL PRDGLPSTSA SAAAAGAAAPA LYPALGLNGL PQLGYQAAVL KEGLPQVYPP
541 YLNLYLRPDSE ASQSPQYSFE SLPQKICLIC GDEASGCHYG VLTCGSCKVF EKRAMEGQHN
601 YLCAGRNDI VDKIRRKNCP ACRLRKCCQA GMVLGGRKFK KFNKVRVVRA LDAVALPQPL
661 GVPNESQALS QRFTFSPGQD IQLIPPLINL LMSIEPDVIY AGHDNTKPDT SSSLLTSLNQ
721 LGERQLLSVV KWSKSLPGFR NLHIDDOITL IQYSWMSLMV FGLGWRSYKH VSGQMLYFAP
781 DLILNEQRMK ESSFYSLCLT MWQIPOEFVK LOVSQEEFLC MKVLLLNTI FLEGLRSQTO
841 FEEMRSSYIR ELIKAIGLRQ KGVVSSSQRF YQLTKLLDNL HDLVKQLHLY CLNTFIQSRA
901 LSVEFPEMMS EVIAAQLPKI LAGMVKPLLF HKK

Fig. 20

1 ctgaccagcg ccgcccctcc 241 cccaggagggt ggagatccct ccggccatc
 61 cacattcaac acccaacttc 246 tcccctatct tcccggaaacc ccctccctct
 121 tccctttcc ctcctccctg 251 gagacggggg aggagaaaag ggagatccag tcgtcatgac
 181 tgagctgaag 256 gcaaagggtc 257 cccgggctcc 258 ccacgtggcg 259 ggcggcccg
 241 ggtcgatcc 264 ccactgctgt 265 gtcggccagc 266 cgcaggctcg 267 ttcccggga
 301 ggacaccc 272 cctgaagtt 273 cggccatacc 274 tatctccctg 275 gacgggctac 276 tcttccctcg
 361 gcccgtcc 282 ggacaggacc 283 cctccgacga 284 aaagacgcag 285 gaccagcagt 286 cgctgtcgga
 421 cgtggagg 292 gcatattcca 293 gagctgaagc 294 tacaagggt 295 gctggaggca 296 gcagtctag
 481 tccccca 298 aaggacagcg 300 gactgctgga 301 cagtgtctt 302 gacactctgt 303 tggcgcctc
 541 aggtccccc 308 cagagccaac 310 ccagccctcc 311 cgcctgcgag 312 gtcaccagct 313 ttgggtgcct
 601 gtttggccc 318 gaactcccc 320 aagatccacc 321 ggctgcccc 322 gccaccc 323 ggggttgc
 661 cccgctcatg 338 agccggtcc 340 ggtgcaaggt 341 tggagacagc 342 tccgggacgg 343 cagctgcca
 721 taaagtgt 348 ccccgggg 350 tgcaccagc 351 cccggcagctg 352 ctgctcccg 353 cctctgagag
 781 ccctcactgg 358 tccgggg 360 cagtgaagcc 361 gtctccgcag 362 gccgctgcgg 363 tggaggttga
 841 ggaggaggat 368 ggctctgagt 370 ccgaggagtc 371 tgccggtcc 372 ctctgaagg 373 gcaaaccctcg
 901 ggctctgggt 378 ggccggcc 380 ctggaggagg 381 aqccgcggct 382 gtcccggc 383 gggcggc
 961 aggaggcg 388 gcccctgg 390 ccaaggaaga 391 tccccgttc 392 tca 393 gggcggcc
 1021 ggtggagc 398 gacgcgc 400 tggggcc 401 ggcgtcccc 402 ctggccacca 403 cggtgatgga
 1081 tttcatcc 408 gtgcctatcc 410 tgcctctcaa 411 tcacgccta 412 ttggcagccc 413 gca 414
 1141 gtcgtgaa 420 gacgaaagg 422 acgacggc 423 ggccggg 424 gca 425 gggcc
 1201 gcccgttca 430 ccctgtgc 432 cgtccaccc 433 ggtcgtgt 434 ggcacttcc 435 cgcactgc
 1261 gtacccgccc 440 gacgcgc 442 ccaaggacga 443 aggcgcgg 444 gctcccg 445 gtc
 1321 gcccgtcta 450 aagataaa 452 aggaggagg 453 agc 454 gat 455 tggggcc
 1381 ttcttac 460 gtggccgg 462 ccaaccc 463 agc 464 tccc 465 gat
 1441 gccccgtg 470 cccgcgc 472 cgcaccc 473 cagaccc 474 gaa 475 tggggcc
 1501 acccgcc 480 cgcct 482 cgtcg 483 ctcc 484 tcc 485 ccc
 1561 gtacaa 490 agggcgc 492 cgc 493 ggg 494 ccc 495 ccc
 1621 gcccggc 500 agcgc 502 tgc 503 gac 504 ccc 505 ccc
 1681 cggccgc 510 gggcgc 512 cgcgc 513 ccc 514 ccc 515 ccc
 1741 gtcggctac 520 caggccgc 522 tgctca 523 taaaatcc 524 agaaaaa
 1801 caactac 530 aggccgg 532 caga 533 ggtcctt 534 ggtcgaaa
 1861 acctc 540 aggtt 542 tctgtgg 543 tgctgtt 544 ctccc
 1921 tacctgt 550 ggtt 552 agctgt 553 gat 554 tca
 1981 atgtgt 560 ggtt 562 agaaat 563 gat 564 tca
 2041 tcgcctt 570 aagtgt 572 aggtgg 573 gat 574 tca
 2101 caataa 580 aggtgt 582 gac 583 tgc 584 cattgg
 2161 tccaaat 590 gacca 592 agccc 593 taagg 594 atc
 2221 gttgat 600 cact 602 gatc 603 acctgtt 604 attactt
 2281 acatgaca 610 aaaaa 612 acac 613 ctc 614 tca
 2341 cgagagg 620 cttctt 622 ctagt 623 tcttt
 2401 acatattg 630 gacc 632 gataa 633 ctctcatt
 2461 tcttaggat 640 ggat 642 cctaca 643 aacatgt
 2521 aatacta 650 aat 652 gac 653 tca
 2581 gcagat 660 ccc 662 ccc 663 tca
 2641 agtattgt 670 tta 672 aata 673 caatt
 2701 ggagatg 680 tca 682 agtaca 683 tt
 2761 agttgt 690 tca 692 gtttctatca 693 actt
 2821 tcttgc 700 taaa 702 ttttgc 703 ttttgc
 2881 ttttgc 710 ttttgc 712 ttttgc 713 ttttgc
 2941 agggatgg 720 ttttgc 722 ttttgc 723 ttttgc

Fig. 21

SEQUENCE LISTING

<110> Theragene Biomedical Laboratories GmbH

5 <120> Hormone-Hormone Receptor Complexes and Nucleic Acid
Constructs and Their Use in Gene Therapy

<130> 000065wo/JH/ml

10 <140>
<141>

<160> 19

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 5753

20 <212> DNA

<213> Artificial Sequence

<220>

25 <223> Description of Artificial Sequence: vector pTGF36

<220>

<221> CDS

<222> (689)..(2071)

30 <400> 1

cgcgttgaca ttgattattt actagttatt aatagtaatc aattacgggg tcattagttc 60

atagccata tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac 120

35 cgcccaacga ccccccggccca ttgacgtcaa taatgacgta tgttccata gtaacgccaa 180

tagggacttt ccattgacgt caatgggtgg agtatttacg gtaaaactgcc cacttggcag 240

40 tacatcaagt gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtttatggc 300

ccgcctggca ttatgcccag tacatgacct tatggactt tcctacttgg cagttacatct 360

acgtattttt catcgctatt accatggtga tgcgggttttgc agtacatc aatgggcgtg 420

45 gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc aatgggagtt 480

tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc gccccattga 540

50 cgcaaatggg cggtagggcgt gtacgggtgg aggtctatat aagcagagct ctctggctaa 600

ctagagaacc cactgcttac tggcttatcg aaattaatac gactcactat agggagaccc 660

aagcttgcattt gccaattccg caaagggtt atg cag cgc gtg aac atg atc atg 712

Met Gln Arg Val Asn Met Ile Met
1 5

55 gca gaa tca cca ggc ctc atc acc atc tgc ctt tta gga tat cta ctc 760
Ala Glu Ser Pro Gly Leu Ile Thr Ile Cys Leu Leu Gly Tyr Leu Leu

10

15

20

60

·	agt gct gaa tgt aca gtt ttt ctt gat cat gaa aac gcc aac aaa att	808		
25	Ser Ala Glu Cys Thr Val Phe Leu Asp His Glu Asn Ala Asn Lys Ile			
	30	35	40	
5	ctg aat cgg cca aag agg tat aat tca ggt aaa ttg gaa gag ttt gtt	856		
	Leu Asn Arg Pro Lys Arg Tyr Asn Ser Gly Lys Leu Glu Glu Phe Val			
	45	50	55	
10	caa ggg aac ctt gag aga gaa tgt atg gaa gaa aag tgt agt ttt gaa	904		
	Gln Gly Asn Leu Glu Arg Glu Cys Met Glu Glu Lys Cys Ser Phe Glu			
	60	65	70	
15	gaa gca cga gaa gtt ttt gaa aac act gaa aga aca act gaa ttt tgg	952		
	Glu Ala Arg Glu Val Phe Glu Asn Thr Glu Arg Thr Thr Glu Phe Trp			
	75	80	85	
20	aag cag tat gtt gat gga gat cag tgt gag tcc aat cca tgt tta aat	1000		
	Lys Gln Tyr Val Asp Gly Asp Gln Cys Glu Ser Asn Pro Cys Leu Asn			
	90	95	100	
	ggc ggc agt tgc aag gat gac att aat tcc tat gaa tgt tgg tgg tgg ccc	1048		
	Gly Gly Ser Cys Lys Asp Asp Ile Asn Ser Tyr Glu Cys Trp Cys Pro			
	105	110	115	120
25	ttt gga ttt gaa gga aag aac tgt gaa tta gat gta aca tgt aac att	1096		
	Phe Gly Phe Glu Gly Lys Asn Cys Glu Leu Asp Val Thr Cys Asn Ile			
	125	130	135	
30	aag aat ggc aga tgc gag cag ttt tgt aaa aat agt gct gat aac aag	1144		
	Lys Asn Gly Arg Cys Glu Gln Phe Cys Lys Asn Ser Ala Asp Asn Lys			
	140	145	150	
35	gtg gtt tgc tcc tgt act gag gga tat cga ctt gca gaa aac cag aag	1192		
	Val Val Cys Ser Cys Thr Glu Gly Tyr Arg Leu Ala Glu Asn Gln Lys			
	155	160	165	
40	tcc tgt gaa cca gca gtg cca ttt cca tgt gga aga gtt tct gtt tca	1240		
	Ser Cys Glu Pro Ala Val Pro Phe Pro Cys Gly Arg Val Ser Val Ser			
	170	175	180	
45	caa act tct aag ctc acc cgt gct gag act gtt ttt cct gat gtg gac	1288		
	Gln Thr Ser Lys Leu Thr Arg Ala Glu Thr Val Phe Pro Asp Val Asp			
	185	190	195	200
50	tat gta aat tct act gaa gct gaa acc att ttg gat aac atc act caa	1336		
	Tyr Val Asn Ser Thr Glu Ala Glu Thr Ile Leu Asp Asn Ile Thr Gln			
	205	210	215	
55	agc acc caa tca ttt aat gac ttc act cgg gtt ggt gga gaa gat	1384		
	Ser Thr Gln Ser Phe Asn Asp Phe Thr Arg Val Val Gly Gly Glu Asp			
	220	225	230	
	gcc aaa cca ggt caa ttc cct tgg cag gtt gtt ttg aat ggt aaa gtt	1432		
	Ala Lys Pro Gly Gln Phe Pro Trp Gln Val Val Leu Asn Gly Lys Val			
	235	240	245	
60	gat gca ttc tgt gga ggc tct atc gtt aat gaa aaa tgg att gta act	1480		
	Asp Ala Phe Cys Gly Gly Ser Ile Val Asn Glu Lys Trp Ile Val Thr			
	250	255	260	

gct	gcc	cac	tgt	gtt	gaa	act	ggt	gtt	aaa	att	aca	gtt	gtc	gca	ggt	1528	
Ala	Ala	His	Cys	Val	Glu	Thr	Gly	Val	Lys	Ile	Thr	Val	Val	Ala	Gly		
265				270					275					280			
5	gaa	cat	aat	att	gag	gag	aca	gaa	cat	aca	gag	caa	aag	cga	aat	gtg	1576
	Glu	His	Asn	Ile	Glu	Glu	Thr	Glu	His	Thr	Glu	Gln	Lys	Arg	Asn	Val	
				285					290					295			
10	att	cga	att	att	cct	cac	cac	aac	tac	aat	gca	gct	att	aat	aag	tac	1624
	Ile	Arg	Ile	Ile	Pro	His	His	Asn	Tyr	Asn	Ala	Ala	Ile	Asn	Lys	Tyr	
				300					305					310			
15	aac	cat	gac	att	gcc	ctt	ctg	gaa	ctg	gac	gaa	ccc	tta	gtg	cta	aac	1672
	Asn	His	Asp	Ile	Ala	Leu	Leu	Glu	Leu	Asp	Glu	Pro	Leu	Val	Leu	Asn	
				315					320					325			
20	agc	tac	gtt	aca	cct	att	tgc	att	gct	gac	aag	gaa	tac	acg	aac	atc	1720
	Ser	Tyr	Val	Thr	Pro	Ile	Cys	Ile	Ala	Asp	Lys	Glu	Tyr	Thr	Asn	Ile	
				330					335					340			
25	ttc	ctc	aaa	ttt	gga	tct	ggc	tat	gta	agt	ggc	tgg	gga	aga	gtc	ttc	1768
	Phe	Leu	Lys	Phe	Gly	Ser	Gly	Tyr	Val	Ser	Gly	Trp	Gly	Arg	Val	Phe	
				345					350					355			
30	cac	aaa	ggg	aga	tca	gct	tta	gtt	ctt	cag	tac	ctt	aga	gtt	cca	ctt	1816
	His	Lys	Gly	Arg	Ser	Ala	Leu	Val	Leu	Gln	Tyr	Leu	Arg	Val	Pro	Leu	
				365					370					375			
35	gtt	gac	cga	gcc	aca	tgt	ctt	cg	tct	aca	aag	ttc	acc	atc	tat	aac	1864
	Val	Asp	Arg	Ala	Thr	Cys	Leu	Arg	Ser	Thr	Lys	Phe	Thr	Ile	Tyr	Asn	
				380					385					390			
40	aac	atg	ttc	tgt	gct	ggc	ttc	cat	gaa	gga	ggt	aga	gat	tca	tgt	caa	1912
	Asn	Met	Phe	Cys	Ala	Gly	Phe	His	Glu	Gly	Gly	Arg	Asp	Ser	Cys	Gln	
				395					400					405			
45	gga	gat	agt	ggg	gga	ccc	cat	gtt	act	gaa	gtg	gaa	ggg	acc	agt	ttc	1960
	Gly	Asp	Ser	Gly	Gly	Pro	His	Val	Thr	Glu	Val	Glu	Gly	Thr	Ser	Phe	
				410					415					420			
50	tta	act	gga	att	att	agc	tgg	ggt	gaa	gag	tgt	gca	atg	aaa	ggc	aaa	2008
	Leu	Thr	Gly	Ile	Ile	Ser	Trp	Gly	Glu	Glu	Cys	Ala	Met	Lys	Gly	Lys	
				425					430					435			
55	tat	gga	ata	tat	acc	aag	gta	tcc	cg	tat	gtc	aac	tgg	att	aag	gaa	2056
	Tyr	Gly	Ile	Tyr	Thr	Lys	Val	Ser	Arg	Tyr	Val	Asn	Trp	Ile	Lys	Glu	
				445					450					455			
60	aaa	aca	aag	ctc	act	taatggatc	gtcgagccg	ccgcgactct	actagaggat								2111
	Lys	Thr	Lys	Leu	Thr												
				460													
	ctttgtgaag	gaaccttact	tctgtgggt	gacataattg	gacaaactac	ctacagagat											2171
	ttaaagctct	aaggtaaata	taaaaatttt	aagtgtataa	tgtgttaaac	tactgattct											2231
	aattgtttgt	gtattttaga	ttccaaccta	tggactgtat	gaatgggagc	agtggtgaa											2291
	tgccttaat	gaggaaaacc	tgttttgctc	agaagaaaatg	ccatcttagt	atgatgaggc											2351
	tactgctgac	tctcaacatt	ctactcctcc	aaaaaagaag	agaaaggtag	aagaccccaa											2411

ggactttcct tcagaattgc taagttttt gagtcatgct gtgttagta atagaactct 2471
tgcttgctt gctatttaca ccacaaagga aaaagctgca ctgctataca agaaaattat 2531
5 ggaaaaatata tctgtAACCT ttataagtag gcataacagt tataatcata acatactgtt 2591
ttttcttact ccacacaggc atagagtgtc tgcttataat aactatgctc aaaaattgtg 2651
10 tacctttagc ttttaattt gtaaagggt taataaggaa tatttgatgt atagtgcctt 2711
gactagagat cataatcagc cataccacat ttgttagaggt tttacttgct taaaaaaacc 2771
tcccacacact cccctgaac ctgaaacata aaatgaatgc aattgttgtt gttaacttgt 2831
15 ttattgcagc ttataatggc tacaataaaa gcaatagcat cacaatttc acaaataaag 2891
catttttc actgcattct agttgtgggt tgtccaaact catcaatgtt tcttatcatg 2951
20 tctggatccc cgggtaccct cttagagcgaa ttaattcact ggccgtcggt ttacaacgctc 3011
gtgactggga aaaccctggc gttacccaac ttaatcgct tgcagcacat cccctttcg 3071
ccagctggcg taatagcgaa gaggcccgcg ccgatcgccc ttcccaacag ttgcgcagcc 3131
25 tgaatggcga atggcgcttgc atgcggattt ttctccttac gcattgtgc ggtatttcac 3191
accgcataatg gtgcactctc agtacaatct gctctgatgc cgcatagttt agccagcccc 3251
30 gacacccgccc aacacccgct gacgcgcctt gacgggcttgc tctgctcccg gcatccgctt 3311
acagacaagc tgtgaccgtc tccggagct gcatgtgtca gaggtttca ccgtcatcac 3371
cgaaacgcgc gagacgaaag ggggggtacc agcttcgttag cttagaacatc atgttctggg 3431
35 atatcagctt cgtagctaga acatcatgtt ctggtaaaaa cctcggtata cgccatattt 3491
tataaggtaa tgtcatgata ataatggttt cttagacgtc aggtggact tttcggggaa 3551
40 atgtgcgcgg aacccttattt tggtaaaaa tctaaataca ttcaaataatg tatccgctca 3611
tgagacaata accctgataa atgcttcaat aatattgaaa aaggaagagt atgagtattc 3671
aacatttccg tgccgcctt atccctttt ttgcggcatt ttgccttcct gttttgctc 3731
45 acccagaaac gctggtaaaa gtaaaagatc ctgaagatca gttgggtgca cgagtgggtt 3791
acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcggcc gaagaacgctt 3851
50 ttccaaatgt gggactttt aaagttctgc tatgtggcgc ggtattatcc cgtattgacg 3911
ccgggcaaga gcaactcggt cgccgcatac actattctca gaatgacttgc gttgagttact 3971
caccagtcac agaaaagcat cttagggatg gcatgacagt aagagaattt tgcaatgtcg 4031
55 ccataaccat gagtgataac actgcggcca acttacttct gacaacgatc ggaggaccga 4091
aggagctaac cgctttttt cacaacatgg gggatcatgt aactcgctt gatcggtggg 4151
60 aaccggagct gaatgaagcc ataccaaacc acgagcgtga caccacgatc cctgttagcaa 4211
tggcaacaac gttgcgcggaa ctatatactg gcaactact tactcttagt tcccgcaac 4271

aattaataga ctggatggag gcggataaaag ttgcaggacc acttctgcgc tcggcccttc 4331
 cggctggctg gtttattgct gataaatctg gagccggta gcgtgggtct cgccgtatca 4391
 5 ttgcagcact gggccagat gtaagccct cccgtatcgt agttatctac acgacgggaa 4451
 gtcaggcaac tatggatgaa ccaaataagac agatcgctga gataggtgcc tcactgatta 4511
 10 agcattggta actgtcagac caagtttact catatatact ttagattgtat taaaacttc 4571
 attttaatt taaaaggatc taggtgaaga tccttttga taatctcatg accaaaatcc 4631
 cttaacgtga gtttcgttc cactgagcgt cagacccgt agaaaagatc aaaggatctt 4691
 15 cttagatcc ttttttctg cgctaatct gctgcttgca aaaaaaaaaa ccaccgctac 4751
 cagcggtggt ttgttgccg gatcaagagc taccacttct tttccgaag gtaactggct 4811
 tcagcagagc gcagatacca aatactgttc ttcttagtgcg gccgtagttt ggccaccact 4871
 20 tcaagaactc ttagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg 4931
 ctgccagtg cgataagtgc tgccttaccc ggttggactc aagacgatag ttaccggata 4991
 25 aggccgcagcg gtcgggctga acgggggggtt cgtgcacaca gcccagctt gaggcaacga 5051
 cctacaccga actgagatac ctacagcgtg agctatgaga aagcgccacg cttccgaaag 5111
 30 ggagaaaggc ggacaggtat ccggtaagcg gcagggtcgg aacaggagag cgcacgaggg 5171
 agctccagg gggaaacgcc tggtatctt atagtcctgt cgggttcgc cacctctgac 5231
 ttgagcgtcg atttttgtga tgctcgta gggggcggag cctatggaaa aacgccagca 5291
 35 acgcggcctt ttacggttc ctggcctttt gctggccttt <g>ctcacatg ttcttcctg 5351
 cgttatcccc tgattctgtg gataaccgtt ttaccgcctt tgagtgagct gataccgctc 5411
 40 gccgcagccg aacgaccgag cgcagcgtg cagtgagcga ggaagcggaa gagcgcacaa 5471
 tacgcaaacc gcctctcccc gcgcgttggc cgattcatta atgcagctgg cacgacaggt 5531
 ttcccgactg gaaagcgggc agtgagcgcgca acgcaattaa tggatgttag ctcactcatt 5591
 45 aggccacccca ggctttacac ttatgcctt cggctcgtat gttgtgtgaa attgtgagcg 5651
 gataacaatt tcacacagga aacagctatg accatgatta cgccaaagctc tctagagctc 5711
 tagagctcta gagctctaga gagcttgcat gcctgcaggt cg 5753

<210> 2

<211> 461

<212> PRT

55 <213> Artificial Sequence

<223> Description of Artificial Sequence: vector pTGF36

<400> 2

Met Gln Arg Val Asn Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr

60 1

5

10

15

	Ile	Cys	Leu	Leu	Gly	Tyr	Leu	Leu	Ser	Ala	Glu	Cys	Thr	Val	Phe	Leu
	20								25							30
5	Asp	His	Glu	Asn	Ala	Asn	Lys	Ile	Leu	Asn	Arg	Pro	Lys	Arg	Tyr	Asn
			35						40							45
	Ser	Gly	Lys	Leu	Glu	Glu	Phe	Val	Gln	Gly	Asn	Leu	Glu	Arg	Glu	Cys
			50						55							60
10	Met	Glu	Glu	Lys	Cys	Ser	Phe	Glu	Glu	Ala	Arg	Glu	Val	Phe	Glu	Asn
			65						70							80
	Thr	Glu	Arg	Thr	Thr	Glu	Phe	Trp	Lys	Gln	Tyr	Val	Asp	Gly	Asp	Gln
15										85						95
	Cys	Glu	Ser	Asn	Pro	Cys	Leu	Asn	Gly	Gly	Ser	Cys	Lys	Asp	Asp	Ile
									100							110
20	Asn	Ser	Tyr	Glu	Cys	Trp	Cys	Pro	Phe	Gly	Phe	Glu	Gly	Lys	Asn	Cys
									115							125
	Glu	Leu	Asp	Val	Thr	Cys	Asn	Ile	Lys	Asn	Gly	Arg	Cys	Glu	Gln	Phe
									130							140
25	Cys	Lys	Asn	Ser	Ala	Asp	Asn	Lys	Val	Val	Cys	Ser	Cys	Thr	Glu	Gly
									145							160
	Tyr	Arg	Leu	Ala	Glu	Asn	Gln	Lys	Ser	Cys	Glu	Pro	Ala	Val	Pro	Phe
30									165							175
	Pro	Cys	Gly	Arg	Val	Ser	Val	Ser	Gln	Thr	Ser	Lys	Leu	Thr	Arg	Ala
									180							190
35	Glu	Thr	Val	Phe	Pro	Asp	Val	Asp	Tyr	Val	Asn	Ser	Thr	Glu	Ala	Glu
									195							205
	Thr	Ile	Leu	Asp	Asn	Ile	Thr	Gln	Ser	Thr	Gln	Ser	Phe	Asn	Asp	Phe
									210							220
40	Thr	Arg	Val	Val	Gly	Gly	Glu	Asp	Ala	Lys	Pro	Gly	Gln	Phe	Pro	Trp
									225							240
	Gln	Val	Val	Leu	Asn	Gly	Lys	Val	Asp	Ala	Phe	Cys	Gly	Gly	Ser	Ile
45									245							255
	Val	Asn	Glu	Lys	Trp	Ile	Val	Thr	Ala	Ala	His	Cys	Val	Glu	Thr	Gly
									260							270
50	Val	Lys	Ile	Thr	Val	Val	Ala	Gly	Glu	His	Asn	Ile	Glu	Glu	Thr	Glu
									275							285
	His	Thr	Glu	Gln	Lys	Arg	Asn	Val	Ile	Arg	Ile	Ile	Pro	His	His	Asn
									290							300
55	Tyr	Asn	Ala	Ala	Ile	Asn	Lys	Tyr	Asn	His	Asp	Ile	Ala	Leu	Leu	Glu
									305							320
	Leu	Asp	Glu	Pro	Leu	Val	Leu	Asn	Ser	Tyr	Val	Thr	Pro	Ile	Cys	Ile
60									325							335
	Ala	Asp	Lys	Glu	Tyr	Thr	Asn	Ile	Phe	Leu	Lys	Phe	Gly	Ser	Gly	Tyr
									340							350

Val Ser Gly Trp Gly Arg Val Phe His Lys Gly Arg Ser Ala Leu Val
 355 360 365

5 Leu Gln Tyr Leu Arg Val Pro Leu Val Asp Arg Ala Thr Cys Leu Arg
 370 375 380

Ser Thr Lys Phe Thr Ile Tyr Asn Asn Met Phe Cys Ala Gly Phe His
 385 390 395 400

10 Glu Gly Gly Arg Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro His Val
 405 410 415

Thr Glu Val Glu Gly Thr Ser Phe Leu Thr Gly Ile Ile Ser Trp Gly
 420 425 430

Glu Glu Cys Ala Met Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Ser
 435 440 445

15 20 Arg Tyr Val Asn Trp Ile Lys Glu Lys Thr Lys Leu Thr
 450 455 460

<210> 3
 25 <211> 78
 <212> DNA
 <213> Homo sapiens

<400> 3
 30 ggggtaccag cttcgtagct agaacatcat gttctggat atcagcttcg tagctagaac 60
 atcatgttct ggtacccc 78

<210> 4
 35 <211> 78
 <212> DNA
 <213> Homo sapiens

<400> 4
 40 ggggtaccag aacatgatgt tctagctacg aagctgatat cccagaacat gatgttctag 60
 ctacgaagct ggtacccc 78

<210> 5
 45 <211> 19
 <212> DNA
 <213> Homo sapiens

<400> 5
 50 agcttgacct cgagcaagc 19

<210> 6
 55 <211> 19
 <212> DNA
 <213> Homo sapiens

<400> 6
 60 ggccgcttgc tcgaggta 19

5 <210> 7
 <211> 43
 <212> DNA
 <213> Homo sapiens
10 <400> 7
 ggaattccgc aaaggttatg cagcgcgtga acatgatcat ggc 43
15 <210> 8
 <211> 39
 <212> DNA
 <213> Homo sapiens
20 <400> 8
 cgcgatcca ttaagtgagc tttgttttt ccttaatcc 39
25 <210> 9
 <211> 26
 <212> DNA
 <213> Homo sapiens
30 <400> 9
 cgaggatcca gtcgtcatga ctgagc 26
35 <210> 10
 <211> 41
 <212> DNA
 <213> Homo sapiens
40 <400> 10
 gcagaattca ttataaaaac tcaagacctc ataatcctga c 41
45 <210> 11
 <211> 20
 <212> DNA
 <213> Homo sapiens
50 <400> 11
 ctcctcgggg tcgaccctgg 20
55 <210> 12
 <211> 20
 <212> DNA
 <213> Homo sapiens
60 <400> 12
 ccagggtcga ccccgaggag 20
65 <210> 13
 <211> 5905
 <212> DNA
 <213> Artificial Sequence
70 <220>
 <223> Description of Artificial Sequence: vector pTGF53

<400> 13

	cgcgtt	gaca	ttgattattt	actagttatt	aatagaatc	aattacgggg	tcattagttc	60			
	atagccc	ata	tatggagttc	cgcg	tta	aacttacgt	aatggcccg	cctggctgac	120		
	cggccaa	cgt	ccccgc	ccca	ttgacgt	caatgggtt	agtatttacg	gtaaactgcc	180		
5	taggactt	tt	ccattgacgt	caatgggtt	gtat	gacgt	tgttcc	cata	gtaa	cgttgc	240
	tacatca	at	ccat	tgacgt	ccaa	gtat	cccttatt	gtcaat	gttcaat	aatgggat	300
	ccgcctgg	cc	ttatgccc	tgacgt	ccaa	cccttatt	gtctcc	acc	gttcaat	aatgggat	360
	acgtattt	tt	catcg	accatgg	tgcc	tgcc	tgcc	tgcc	tgcc	tgcc	420
	gatagcggt	tg	tgact	tgact	ggat	tgact	gtctcc	acc	tgact	tgact	480
10	tgtttggc	ca	ccaaaat	ccgg	tttc	ccaaat	gtcg	taa	acaact	cccccatt	540
	cgcaaat	cg	cggt	agg	tttc	cggt	tttc	tttc	tttc	tttc	600
	ctagagaacc	ct	actg	tttc	tttc	tttc	tttc	tttc	tttc	tttc	660
	aagcttgc	cc	ccaatt	ccaa	tttc	tttc	tttc	tttc	tttc	tttc	720
	accaggc	cc	atc	ccat	tttc	tttc	tttc	tttc	tttc	tttc	780
15	tcttgatcat	tt	aaaaac	ccca	aaaaat	tttc	tttc	tttc	tttc	tttc	840
	atttgaagag	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	900
	tgaagaagca	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	960
	tgttgc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1020
	cattaattcc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1080
20	tgtaacatgt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1140
	caaggtggtt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1200
	accacgatg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1260
	tgctgagact	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1320
	ggataaacatc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1380
25	agatgccaaa	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1440
	ctgtggaggc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1500
	tgggtttaaa	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1560
	gcaaaagcga	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1620
	gtacaaccat	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1680
30	tacacattt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1740
	ctatgttaat	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1800
	ccttagagtt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1860
	taacaacatg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1920
	tggggaccc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	1980
35	gggtgaagag	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2040
	caactggatt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2100
	tactagagga	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2160
	cctacagaga	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2220
	ctactgattc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2280
40	cagtggtgg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2340
	gatgtgagg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2400
	gaagacccca	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2460
	aatagaactc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2520
	aagaaaattt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2580
45	aacatactgt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2640
	aaaaatttgt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2700
	tatagtgc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2760
	ttttaaaaac	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2820
	tgttaactt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2880
50	cacaataaa	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	2940
	atcttatcat	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3000
	ggatatacg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3060
	ttcactggcc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3120
	tcgccttgca	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3180
55	tcgccttcc	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3240
	cattacgat	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3300
	tgtatccgca	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3360
	ggcttgtctg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3420
	gtgtcagagg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3480
60	acatgatgtt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3540
	gtaccccg	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3600
	tttagacgtca	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	3660

5 ctaaatacat tcaaataatgt atccgctcat gagacaataa ccctgataaa tgcttcaata 3720
 atattgaaaa aggaagagta tgagtattca acatttcgt gtcgcctta ttccctttt 3780
 tgccgcattt tgccttcctg ttttgctca cccagaaaacg ctggtgaaag taaaagatgc 3840
 tgaagatca gttgggtgcac gagtgggtt catcgactg gatctcaaca gcggtaaagat 3900
 10 ccttgagagt ttccgcggc aagaacgtt tccaatgtat agcactttt aagttctgt 3960
 atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca 4020
 ctattctcag aatgacttgg ttgagtaactc accagtcaca gaaaagcatc ttacggatgg 4080
 catgacagta agagaattat gcagtgcgc cataaccatg agtgataaca ctgcggccaa 4140
 cttaattctg acaacgatcg gaggaccgaa ggagctaacc gctttttgc acaaactggg 4200
 15 ggtatcatgt aactcgcttg atcgttggg accggagctg aatgaagcca taccaaacga 4260
 cgagcgtgac accacgatgc ctgttagcaat ggcaacaacg ttgcgcaaaac tattaactgg 4320
 cgaactactt actctagctt cccggcaaca attaataagac tggatggagg cggataaagt 4380
 tcaggagcca cttctgcgt cggcccttcc ggctggctgg ttatttctg ataaatctgg 4440
 20 agccggtag cgtgggtctc gcggtatcat tgcaagactg gggccagatg gtaagccctc 4500
 ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca 4560
 gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc 4620
 atataatactt tagattgatt taaaatttca ttttaattt aaaaggatct agtgaagat 4680
 cctttttgtat aatctcatga cccaaatccc ttaacgttag ttttcgttcc actgagcgctc 4740
 25 agaccccgta gaaaagatca aaggatctt ttgagatctt tttttctgc gcttaatctg 4800
 ctgcttgcaaa aaaaaaaaaac caccgctacc agcgggtggg ttttgcggg atcaagagct 4860
 accaactctt tttccgaagg taactggott cagcagagcg tctagtgtag ccgtagttag gccaccactt caagaactct 4920
 cgctctgcta atcctgttac cagtggctgc tgccagtggc gataagtcgt gcttaccgg 4980
 gttggactca agacgatagt tacggataag ggcgacggc tacaccgaaac 5040
 30 tgcacacagc ccagcttggc gccaacgacc tacaccgaaac caggtatcc ggtaaagccgc 5100
 ctatgagaaa ggcgcacgc tccccgaaggg agaaaggccg ctaggttccct 5160
 agggctggaa caggagagcg cacgaggagg ctccaggccc 5220
 agtccctgtcg ggtttcgcca cctctgactt gaggctcgat gaaacgcctg 5280
 35 gggcggagcc tatggaaaaa cgccagcaac gcccgccttt ttttgcgtatg ctgcgtcagg 5340
 tggccctttt ctcacatgtt ctttctctgcg ttatccccctg tacggttccct 5400
 accgcctttt agtgagctga taccgctgcg cgccggccaa 5460
 gtgagcgagg aagcggaga gcccggccaa cgcggccaaacgc 5520
 attcattaaat gcagctggca cgacagggtt cccgacttggc 5580
 gcaattaaat tgagttactg cactcattag gcaccccgagg aagcgggcag tgagcgcaac 5640
 gctctgtatgt ttttgcgtatgtt gttgtggaaat ttttgcgtatgtt 5700
 catgattacg ccaagctctc tagagctca gagctctaga acacaggaaa cagctatgac 5760
 cgggttacca gcttcgttagc tagaaacatca ttttgcgtatgtt gctctagaga gcttgcattgc 5820
 catcatgttc tggtaccccg gtcga catcatgttc tggtaccccg gtcga 5880
 40 5905

45 <210> 14
 <211> 6052
 <212> DNA
 <213> Artificial Sequence

45. <220>
 <223> Description of Artificial Sequence: vector pTGF64

50 <400> 14
 cgcgttgcata ttgatttattt actagttattt aatagtaatc aattacgggg tcattagttc 60
 atagcccata tatggagttc cgcgttacat aacttacggt aatggcccg cctggctgac 120
 cgcggccaaacga ccccccggccaa ttgacgtcaa taatgacgtt tgccatccata gtaacgcca 180
 tagggactttt ccattgacgtt caatgggtgg agtattttacg taaaactgccc cacttggcag 240
 tacatcaagt gtatcatatg ccaagtacgc cccctatttga cgtcaatgac ggttaaatggc 300
 55 cccgcctggca ttatgcccacg tacatgaccc ttttgcgtatgtt ccctacttgg cagtagatct 360
 acgttattttt catcgctattt accatgggttga tggccgttttgcg cagtagatctt aatgggcgtg 420
 gatacggtt ttttgcgtatgtt gttttggca cccaaatcaa cgggacttttccaaatgtcg taacaactcc gcccatttga 480
 ttttgcgtatgtt gttttggca cccaaatcaa cgggacttttccaaatgtcg taacaactcc gcccatttga 540
 60 cggtaggcgt gtacgggtgg aggtctatata aagcagagct ctctggctaa 600
 ctagagaacc cactcgatcc tggcttacatc aaattaaatc gactcactat agggagaccc 660
 aagcttgcattt gccaatcccg caaagggtt gcaacgcgtg aacatgatca tggcagaatc 720
 accaggccctc atcaccatctt gccttttagg atatctactc agtgcgtatgtt gtcgtatgtt 780

	tcttgatcat	gaaaacgcc	acaaaattct	gaatcgcc	aagaggata	attcaggta	840	
	atggaaagag	tttgttcaag	gaaaccttga	gagagaatgt	atggaaagaaa	agttagttt	900	
	tgaagaagca	cgagaagttt	ttgaaaacac	tgaaagaaca	actgaatttt	ggaagcagta	960	
5	tgttcatgga	gatcagtgt	agtccaatcc	atgtttaat	gcccgcagg	gcaaggatga	1020	
	cattaattcc	tatgaatgtt	ggtgtccctt	tggatttga	gaaaagaact	gtgaattaga	1080	
	tgttaacatgt	aacattaaga	atggcagatg	cgagcagttt	tgtaaaaata	gtgtgtataa	1140	
	caagggtggtt	tgctccgt	ctgagggata	tcgacttgc	gaaaaccaga	agtccctgt	1200	
	accacgatg	ccatttccat	gtgaaagag	ttctgttca	caaacttcta	agctcacc	1260	
10	tgctgagact	gttttccct	atgtggacta	tgtaaattct	actgaagctg	aaaccat	1320	
	ggataacatc	actcaaagca	cccaatcatt	taatgactc	actcgggtt	ttggggaga	1380	
	agatgccaaa	ccaggtaat	tcccttggca	ggttgtttt	aatggtaaag	ttgtgcatt	1440	
	ctgtggaggc	tctatcgta	atgaaaaat	gattgtact	gtgc	gtgtgaaac	1500	
	tgggttaaa	attacagtt	tcgaggatg	acataat	gaggagacag	aacatacaga	1560	
15	gcaaaagcga	aatgtgatc	gaattattcc	tcaccaac	tacaatgcag	ctattaataa	1620	
	gtacaaccat	gacattgccc	ttctggact	ggacgaaacc	ttatgtctaa	acagctacgt	1680	
	tacacattt	tgcatgt	acaaggaata	cacgaacatc	ttccctcaat	ttggatctgg	1740	
	ctatgtaa	ggctggggaa	gagtcttca	caaaggaga	tca	ttcttcagta	1800	
	ccttagagtt	ccacttgg	accgagccac	atgtctcg	tctacaat	tcaccatcta	1860	
20	taacaacatg	ttctgtgt	gttccatga	aggaggata	gattcatgt	aaggagatag	1920	
	tgggggaccc	catgttact	aagtggagg	gaccagttt	ttaactggaa	ttattagct	1980	
	gggtgttgg	tgtcaatg	aaggcaata	tggatata	accaaggat	cccggtatgt	2040	
	caactggatt	aaggaaaaaa	caaagctc	ttaatggat	cggtcgag	gccgcgact	2100	
	tactagagga	tcttggaa	ggaaccttac	ttctgtgg	tgacataatt	ggacaaacta	2160	
	cctcagaga	ttttaagct	taaggtaaat	ataaaat	taagtgtata	atgtgtt	2220	
25	ctactgtt	taattgttt	tgtat	ttttag	attccaa	atggactg	2280	
	cagtgggtt	atgc	tttta	tgaggaaac	ctgttt	cagaagaaat	2340	
	gatgttgg	ctactgt	ctctcaac	tctact	ccct	caaaaaagaa	2400	
	gaagacccca	aggacttcc	ttcagaat	ctaa	tgagtc	tgtgtt	2460	
30	aatagaactc	ttgttgc	tgtat	tttac	accacaa	aaaagctc	actgtatac	2520
	aagaaaatta	tggaaaata	ttctgt	taacc	tttata	ggcataac	ttataatcat	2580
	aacatactgt	tttttcttac	tccacacagg	catagat	gt	ctgtat	taactatgt	2640
	caaaaattgt	gtacctt	cttttaatt	tgtaa	agggg	tttataa	gatattgt	2700
	tatagtgcct	tgactagaga	tcaat	ccat	ttttag	gg	ttttacttgc	2760
35	ttttaaaac	ctcccacacc	tcccctgaa	cctgaa	tttataa	aaaatgaat	caattgtt	2820
	tgttaactt	tttattgc	cttataat	ttaca	tttataa	agcaat	tgacaaattt	2880
	cacaataaaa	gcattttt	cactgcatt	tagt	ttgtgt	ttgtccaa	tcatcaat	2940
	atcttatcat	gtctggat	ccgggggt	ccag	tttataa	tttataa	tcatgttct	3000
	ggatatcagc	ttcgt	gatc	ttctgt	ccct	tttataa	gcaat	3060
40	tcactggccg	tgttttac	acgtcg	tac	tttataa	tttataa	ccaaactt	3120
	cgcccttgcag	cacatcccc	tttgc	ccag	tttataa	tttataa	gcaagaggc	3180
	cgccttccc	aacagtgc	caggctg	aaat	tttataa	tttataa	ccgcacc	3240
	agaacatcat	tttctgg	atcag	tttac	tttataa	tttataa	tttacttgc	3300
	ctgatgcgt	atttctt	tacgc	atc	tttataa	tttataa	tttacttgc	3360
	ctcgtacaa	tctgtct	tgccgc	atc	tttataa	tttataa	tttacttgc	3420
45	gctgacgcgc	cctgacggc	tttgtct	ccgg	tttataa	tttataa	tttacttgc	3480
	gtctccggga	gctgc	atgt	tttataa	tttataa	tttataa	tttacttgc	3540
	aaggcacc	aaacat	gtat	tttataa	tttataa	tttataa	tttacttgc	3600
	gctacgaagc	tggta	ccctgt	tttataa	tttataa	tttataa	tttacttgc	3660
50	ataatggttt	tttagac	agg	tttataa	tttataa	tttataa	tttacttgc	3720
	tgttatttt	tctaaat	ttcaa	tttataa	tttataa	tttataa	tttacttgc	3780
	atgc	tttataa	tttataa	tttataa	tttataa	tttataa	tttacttgc	3840
	attccctttt	tttgc	ggcatt	tttataa	tttataa	tttataa	tttacttgc	3900
	gtaaaagatg	ctgaa	gggt	tttataa	tttataa	tttataa	tttacttgc	3960
55	agcgtt	tttgc	ggat	tttataa	tttataa	tttataa	tttacttgc	4020
	aaagttctgc	tatgt	ggc	tttataa	tttataa	tttataa	tttacttgc	4080
	cggccat	actatt	ctca	tttataa	tttataa	tttataa	tttacttgc	4140
	cttacggat	gtat	gac	tttataa	tttataa	tttataa	tttacttgc	4200
	actcg	actt	tttataa	tttataa	tttataa	tttataa	tttacttgc	4260
60	cacaacatgg	gggat	catgt	tttataa	tttataa	tttataa	tttacttgc	4320
	atacc	tttataa	tttataa	tttataa	tttataa	tttataa	tttacttgc	4380
	cttataact	tttataa	tttataa	tttataa	tttataa	tttataa	tttacttgc	4440
	gcggataaaag	tttataa	tttataa	tttataa	tttataa	tttataa	tttacttgc	4500

5 gataaatctg gagccggtga gcgtgggtct cgccgttatca ttgcagcaact gggccagat 4560
 ggttaagccct cccgtatctg agttatctac acgacgggaa gtcaggcaac tatggatgaa 4620
 cgaaaatagac agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac 4680
 caagttact catataact ttagattgtat taaaacttc atttttaatt taaaaggatc 4740
 taggtgaaga tccttttga taatctcatg accaaaatcc cttaacgtga gtttcgttc 4800
 10 cactgagcgt cagacccgt agaaaaagatc aaaggatctt cttgagatcc ttttttctg 4860
 cgcgtaatct gctgcttgc aacaaaaaaa ccaccgtac cagcgggtgt ttgtttgccc 4920
 gatcaagagc taccaactt tttccgaag gtaactggct tcagcagagc gcagatacca 4980
 aatactgtcc ttcttagtga gccgttagtta ggccaccact tcaagaactc tgcacccg 5040
 15 cctacatacc tcgcctctgt aatcctgtta ccagtgctg ctgcgcgtgg cgataagtcg 5100
 tgccttaccg ggttggactc aagacgatag ttacccgata aggccgcggcg gtcgggctga 5160
 acgggggggtt cgtgcacaca gcccagctt gagcgaacga cctacaccga actgagatac 5220
 ctacacgtg agctatgaga aagcgcacacg cttcccaag ggagaaaaggc ggacaggtat 5280
 20 ccggtaagcg gcagggtcgg aacaggagag cgcacagggg agcttccagg gggaaaacgcc 5340
 tggtatctt atagtcctgt cgggttgcg cacctctgac ttgagcgtcg atttttgcg 5400
 tgctcgtag gggggcggag cctatggaaa aacgcacacg acgcggccctt ttacccgttc 5460
 ctggcctttt gctggccctt tgctcacatg ttcttcctg cggttatcccc tgattctgtg 5520
 gataaccgtt ttaccgcctt tgagttagt gataccgtc gccgcagccg aacgaccgag 5580
 25 cgcacgcgt cagtggcga ggggttaccag aacatgtatc tctagctacg aagctgatat 5640
 cccagaacat gatgttcttag ctacgaagct ggtaccccg cggaaagagcg cccaaatacgc 5700
 aaaccgcctc tccccgcgcg ttggccgatt cattaatgca gctggcacga caggtttccc 5760
 gactggaaag cgggcgtgt ggcacacgc attaatgtga tttagctcac tcattaggca 5820
 ccccaggctt tacactttt gcttcggct cgtatgtt gttggatattt gaggcgatata 5880
 30 caatttcaca caggaaacag ctatgaccat gattacgcca agctctctag agctctagag 5940
 ctctagagct ctagagagct tgcatgcccgg ggtaccagct tgcgttagctag aacatcatgt 6000
 tctggatat cagcttcgtt gctagaacat catgttctgg taccgggtc ga 6052

35 <210> 15
 <211> 4344
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Description of Artificial Sequence: vector pTGF67

45 <400> 15
 cgcgttgcata ttgatttttgc actagttattt aatagaatc aattacgggg tcattagttc 60
 atagccata tatggaggta cgcgttacat aacttacggta aatggcccg cctggctgac 120
 50 cgcccaacga cccccggccca ttgacgtcaa taatgacgtt gtttccata gtaacgcca 180
 tagggacttt ccattgacgt caatgggtgg agtattacg gtaaactgtcc cacttggcag 240
 tacatcaagt gtatcatatg ccaagtacgc ccccttata gtcataatgac gtaaatggc 300
 ccgcctggca ttatgcccac tacatgacct tatggactt tcctacttgg cagtagatct 360
 acgttattgt catcgctatt accatggtga tgcgggttttgc gcaatcatac aatgggcgtg 420
 55 gatagcgggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc aatgggagtt 480
 tggggcata cccaaatcaa cgggactttt caaaatgtcg taacaactcc gccccattga 540
 cgcaaatggg cggtaggggt gtacgggtgg aggtctatata aagcagagct ctctggctaa 600
 ctagagaacc cactgcttac tggcttatcg aaattaatac gactcaactat agggagaccc 660
 aagcttgacc tcgagcaacg ggccgcact ctactagagg atctttgtga aggaaccta 720
 60 cttctgtgggt gtgacataat tggacaaaact acctacagag atttaaagct ctaaggtaaa 780
 tataaaattt ttaagtgtat aatgtgtttaa actactgatt ctaattgttt gtgtatattt 840
 gattccaacc tatggaaactg atgaatggga gcaatgggtgg aatgccttta atgagggaaaa 900
 cctgttttgc tcagaagaaa tggccatctag tggatgttag gctactgctg actctcaaca 960
 ttctacttcc cccaaaaaaa agagaaaaggta agaagacccc aaggacttcc cttcagaatt 1020
 65 gctaagtttt ttgagtcgt ctgtgttttag taatagaact cttgcttgc ttgcttattt 1080
 caccacaaag gaaaaagctg cactgctata caagaaaatt atggaaaaat attctgtaac 1140
 ctttataatgt aggccataaca gttataatca taacataactg tttttcttta ctccacacag 1200
 gcatagagtg tctgcttatacataactatgc tcaaaaattt gttaccccttta gctttttat 1260
 ttgttaaagggt gttataataagg aatatttgcgtt gttatgttgc ttgacttagag atcataatca 1320
 70 gccataccac atttgttagag gttttacttg cttaaaaaaa cttccacac cttccctgt 1380
 acctgaaaaca taaaatgaat gcaattgttg ttgttaactt gttatttgc gcttataatg 1440
 gttacaaata aagcaatagc atcacaattt tcacaaataa agcatttttt tcactgcatt 1500

	ctagttgtgg	tttgcacaaa	ctcatcaatg	tatcttatca	tgtctggatc	ccgggttacc	1560
	ctctagagcg	aattaattca	ctggccgtcg	tttacaacg	tcgtgactgg	aaaaaccctg	1620
5	gcgttaccca	acttaatcgc	cttgcagcac	atccccctt	cgcgcgttgg	cgtaatagcg	1680
	aaggagcccg	caccgatcgc	ccttcccaac	agttgcgcag	cctgaatggc	aatggcgcc	1740
	tgatgcgta	tttctccct	acgcacatgt	gcccgttattc	acaccgcata	tggtgcactc	1800
	tcagtacaat	ctgctctgt	gccgcatagt	taagccagcc	ccgacacccg	ccaacacccg	1860
	ctgacgcgccc	ctgacgggct	tgtctgtcc	cggcatccgc	ttacagacaa	gctgtgaccg	1920
	tctccggag	ctgcatgtgt	cagaggtttt	caccgtcata	accgaaacgc	gcgagacgaa	1980
10	agggggggta	ccagcttcgt	agctagaaca	tcatgttctg	gatatcagc	ttcgtagcta	2040
	gaacatcatg	ttctggtaacc	ccctctgtga	tacgcctatt	tttatacggtt	aatgtcatga	2100
	taataatgtt	ttcttagacg	tcaagggtggca	cttttcgggg	aatgtgcgc	ggaaccccta	2160
	tttggttatt	tttctaataa	cattcaataa	tgtatccgt	catgagacaa	taaccctgtat	2220
	aaatgcttca	ataatattga	aaaagagaaga	gtatgatgt	taacacatttc	cgtgtcgccc	2280
15	ttattccctt	tttgcggca	ttttgccttc	ctgttttgc	tcaccccgaaa	acgctggtga	2340
	aagtaaaaaga	tgctgaagat	cagggtgggt	cacgagttggg	ttacatcgaa	ctggatctca	2400
	acagcggtaa	gatccttgag	agtttcgccc	ccgaagaacg	tttcccaatg	atgagcactt	2460
	ttaaagttct	gctatgtggc	gcgttattat	cccgttattga	cggccggcaaa	gagcaactcg	2520
	gtcggccgcat	acactattct	cagaatgact	tggtttagta	ctcaccagtc	acagaaaagc	2580
20	atcttacgga	tggcatgaca	gtaagagaat	tatgcagtgc	tgccataacc	atgagtgata	2640
	acactgcggc	caacttactt	ctgacaacga	tcggaggacc	gaaggagcta	accgcctttt	2700
	tgcacaacat	gggggatcat	gtaactcgcc	ttgatcggtt	ggaaccggag	ctgaatgaag	2760
	ccataccaaa	cgacgagcgt	gacaccacga	tgcctgttagc	aatggcaaca	acgttgcgca	2820
	aactattaac	tggcgaacta	cttactctag	cttcccgca	acaattaata	gactggatgg	2880
25	aggccgataa	agttgcagga	ccacttctgc	gctcgccct	tccggctggc	tggtttattt	2940
	ctgataaattc	tggagccggt	gagcgtgggt	ctcgcggat	cattgcagca	ctggggccag	3000
	atgtaagcc	ctcccgatc	gtagttatct	acacgacggg	gagtcaggca	actatggatg	3060
	aacgaaatag	acagatcgt	gagataggtt	cctcaactgt	taagcattgg	taactgtcag	3120
	accaagtttta	ctcatataata	ctttagattt	atttaaaact	tcattttaa	tttaaaagga	3180
30	tcttaggtaa	gatcctttttt	gataatctca	tgacaaaaat	cccttaacgt	gagttttcgt	3240
	tccactgagc	gtcagaccccc	gtaaaaaaa	tcaaaggatc	ttcttgagat	cctttttttt	3300
	tgcgcgtaat	ctgctgtttt	caaaacaaaaaa	aaccacgt	accagcgggt	gtttgtttgc	3360
	cgatcaaga	gctaccaact	cttttccga	aggttaactgg	cttcagcaga	gcccagataac	3420
	caaataactgt	tcttcttagt	tagccgttagt	taggccacca	cttcaagaac	tctgttagcac	3480
35	cgcctacata	cctcgctctg	ctaattctgt	taccagtggc	tgttgcctgt	ggcgataagt	3540
	cgtgtcttac	cgggttgac	tcaagacgt	agttacccga	taaggcgcag	cggtcgggct	3600
	gaacgggggg	ttcgtgcaca	cagcccgat	tggagcgaac	gacccatcacc	gaactggat	3660
	acctacagcg	tgagctatga	gaaagcgcac	cgcttccga	agggagaaaag	gcggacaggt	3720
	atccggtaag	cggcagggtc	ggaacaggag	agcgcacgag	ggagcttcca	ggggaaaacg	3780
40	cctggatct	ttatagtctt	gtcggtttt	gccacctctg	acttggcgt	cgattttgt	3840
	gatgtcgtc	aggggggcg	agcctatgg	aaaaccccg	caacgcggcc	ttttacgg	3900
	tcctggcctt	ttgctggcct	tttgctcaca	tgttcttcc	tgcgttatcc	cctgattctg	3960
	tggataaccg	tattaccggc	tttgagttgt	ctgataccgc	tcgcgcgcag	cgaacgaccg	4020
	agcgcagcga	gtcagtgac	gagaagcgg	aagagcgcac	aatacgcaaa	ccgcctctcc	4080
45	ccgcgcgtt	gccgattcat	taatgcgt	ggcacgacag	gtttcccgac	tggaaagcgg	4140
	gcagtggcg	caacgcatt	aatgtgatgt	agtcactca	ttaggcaccc	caggcttac	4200
	actttatgt	tccggctcgt	atgttgcgt	gaatttgcgt	cgataacaa	tttcacacag	4260
	gaaacagcta	tgaccatgtat	tacgccaagc	tctctagagc	tctagagctc	tagactct	4320
	gagagcttgc	atgcctgcag	gtcg				4344

50

<210> 16
<211> 4496
<212> DNA

55

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector pTGF82

60

<400> 16

cgcggtgaca ttgattattt actagttattt aatagtaatc aattacgggg tcattagttc 60
atagccata tatggatgttc cgcgttacat aacttacgtt aatggcccg cctggctgac 120
cgcccaacga ccccccggcca ttgacgtcaa taatgacgtaa tggccata gtaacgcca 180

	tagggacttt	ccattgacgt	caatgggtgg	agtatttacg	gtaaactgcc	cacttggcag	240
	tacatcaagt	gtatcatatg	ccaagtacgc	cccctattga	cgtcaatgac	ggtaaatggc	300
	ccgcctggca	ttatgcccgag	tacatgaccc	tatgggactt	tcctacttgg	cagtagatct	360
5	acgtattagt	catcgctatt	accatggtg	tgcggtttt	gcagtagatc	aatgggcgtg	420
	gatagcgggtt	tgactcacgg	ggatttccaa	gtctccaccc	cattgacgtc	aatgggagtt	480
	tgttttggca	ccaaaatcaa	cgggactttc	caaaatgtcg	taacaactcc	gccccattga	540
	cgc当地atggg	cggtaggcgt	gtacgggtggg	aggtctat	aagcagagct	ctctggctaa	600
	ctagagaacc	cactgcttac	tgcttatacg	aaattaatac	gactcactat	aggagagaccc	660
10	aagcttgacc	tcgagcaagc	ggccgcgact	ctactagagg	atctttgtga	aggaaccta	720
	cttctgtggt	gtgacataat	tggacaaaact	acctacagag	atttaaagct	ctaaggtaaa	780
	tataaaattt	ttaagtgtat	aatgtgttaa	actactgatt	ctaattgttt	gtgtatttt	840
	gattccaacc	tatggactg	atgaatggga	gcagtggtgg	aatgccttta	atgagggaaa	900
	cctgttttgc	tcagaagaaa	tgccatctag	tgtatgttag	gctactgctg	actctcaaca	960
15	ttctactctt	ccaaaaaaga	agagaaaagg	agaagacccc	aaggacttc	cttcagaatt	1020
	gctaattttt	ttgagtcatg	ctgtgttttag	taatagaact	cttgcttgct	ttgttatttt	1080
	caccacaaag	aaaaaagctg	cactgtata	caagaaaatt	atggaaaaat	attctgttaac	1140
	ctttataagt	aggcataaca	gttataatca	taacactatg	tttttctta	ctccacacag	1200
	gcatagatg	tctgtatata	ataactatgc	tc当地aaaattt	tgtaccttta	gcttttaat	1260
20	ttgttaaagg	gttataaagg	aatattttag	gtataatgtcc	ttgactagag	atcataatca	1320
	gccataccac	attttagag	gttttacttg	ctttaaaaaaa	cctcccacac	ctccccctga	1380
	acctgaaaca	taaaatgaat	gcaatttgg	ttgtttaactt	gtttaatttgc	gcttataatg	1440
	gttacaaata	aagcaatagc	atcacaaattt	tcacaaataa	agcattttt	tcactgcatt	1500
	ctagttgtgg	tttgc当地aaa	ctcatcaatg	tatcttatca	tgtctggatc	ccccgggggt	1560
25	accagcttcg	tagctagaac	atcatgttct	gggatatcag	cttcgttagct	agaacatcat	1620
	gttctgttac	ccccctctag	agcgaattaa	ttcactggcc	gtcgttttac	aacgtcgta	1680
	ctgggaaaac	cctggcgta	cccaacttaa	tcgc当地tttgc	gcacatcccc	cttgc当地ccag	1740
	ctggcgtaat	agcgaagagg	cccgccaccga	tc当地cccttcc	caacagttgc	gcagcctgaa	1800
	tggc当地atgg	cgccctgatgc	ggtatttct	ccttaatgc	ctgtcggtt	tttccacaccg	1860
30	catatggtgc	actctcagta	caatctgtc	tgtatgtcc	tagttaagcc	agccccgaca	1920
	ccc当地ccaaca	cccgctgacg	cgccctgacg	ggcttgc当地tgc	ctcccccgc	ccgcttacag	1980
	acaagctgt	accgtctccg	ggagctgtcat	gtgtcagagg	ttttcaccgt	cataccgaa	2040
	acgc当地cgaga	cgaaaggccg	gggttaccaga	acatgtatgt	ctagctacga	agctgatatc	2100
	ccagaacatg	atgttctcag	tacgaagctg	gtacccttgc	ctcgtgat	gccttatttt	2160
35	ataggtaat	gtcatgataa	taatggttt	ttagacgtca	ggtggcactt	ttc当地ggaaa	2220
	tgtgc当地gg	acccttattt	gttattttt	ctaaatacat	tcaaatatgt	atccgctcat	2280
	gagacaataa	ccctgataaa	tgcttcaata	atattaaaaa	aggaagagta	tgagttattca	2340
	acatttccgt	gtc当地ccctta	ttccctttt	tc当地cccttgc	tttttgc当地	2400	
	ccc当地aaacg	ctgggtgaaag	taaaagatgc	tgaagatcag	tttgggtgcac	gagttgggtt	2460
40	catc当地actg	gatctcaaca	gcm当地taagat	ccttggagat	tttgc当地ccg	aaaacgttt	2520
	tccaaatgt	agcacttta	aagttctgt	atgtggc当地	gtattatccc	gtattgacgc	2580
	cgggcaagag	caactcggc	gc当地gcataca	ctatttctag	aatgacttgg	tttagtactc	2640
	accagtcaca	gaaaagcatac	ttacggatgg	catgacagta	agagaattat	gcagtgctgc	2700
	cataaccatg	agtataaca	ctgc当地ccaa	cttacttctg	acaacgatcg	gaggaccgaa	2760
45	ggagctaaacc	gcttttgc	acaacatggg	ggatcatgt	actcgcttgc	atcgatggaa	2820
	accggagctg	aatgaagcca	taccaaaacga	cgagcgtgac	accacgatgc	ctgtatgtt	2880
	ggcaacacaacg	ttgc当地aaac	tattaactgg	c当地aactactt	actctatgtt	ccggcaaca	2940
	attaatagac	tggatggagg	c当地ataaagt	tgc当地ggacca	cttctgc当地	cgcccttcc	3000
	ggcttggctgg	tttattgtc	ataaaatctgg	agccgggtgag	c当地gggttgc	cggtatcat	3060
50	tgc当地actg	gggccc当地atg	gtaaatgttgc	ccgtatgt	gttatctaca	cgacggggag	3120
	tcaggcaact	atggatggac	gaaatagaca	gatcgttgc	ataggatgtt	cactgattaa	3180
	gcatttggtaa	ctgtcgat	aagtttactc	atataatctt	tagattgtt	taaaacttca	3240
	tttttaattt	aaaaggatct	aggttggat	cctttttgt	aatctatgt	ccaaaatccc	3300
	ttaacgttgc	ttttcgatc	actggatgtc	agacccgtt	gaaatgttgc	aaggatctt	3360
55	tttggatgttgc	tttttctgc	cgatgtatgt	gttggactca	acaaaaaaaac	caccgc当地tacc	3420
	agc当地gggtt	tttttgc当地	atcaagatgt	accaacttgc	tttccgat	taactggctt	3480
	cagc当地agcg	cagatacc	atactgttgc	tctatgttgc	ccgtatgttgc	gccaccactt	3540
	caagaactct	gtagcaccgc	ctacatacc	cgcttgc当地	atccgttgc	c当地gggttgc	3600
	tgccatgttgc	gataatgttgc	gttggactca	agacgtatgt	taccggat	c当地gggttgc	3660
60	ggc当地cagcgg	tc当地ggcttgc	cgatggatcc	gtc当地acacag	ccc当地gttgc	agc当地acgc	3720
	ctacaccgaa	ctgatgttgc	tacagcgttgc	gctatgttgc	agc当地ccacgc	ttccc当地aagg	3780
	gagaaaggcg	gacaggat	cggttgc当地	c当地gggttgc	acaggagatgc	gc当地ggggaa	3840
	gttccagg	ggaaacgcct	ggtatcttta	tagtccatgt	gggttgc当地	acctctgtact	3900

5	tgcgtcgaa	ttttgtat	gctcgtaagg	ggggcgagc	ctatggaaaa	acgcccagcaa	3960
	cgcggccttt	ttacggttcc	tggccttttg	ctggcctttt	gctcacatgt	tctttccctgc	4020
	gttatcccct	gattctgtgg	ataaccgtat	taccgccttt	gagtga ^g ctg	ataccgctcg	4080
	cccgagccga	acgaccgagc	gcagcgagtc	agtgagcga ^g	gaagcggaa ^g	agcgc ^{ccc} aa	4140
	acgcaaaccg	cctctcccg	cgcgttggcc	gattcattaa	tgca ^g ctggc	acgacaggtt	4200
	tcccga ^c tgg	aaagcggca	gtgagc ^g caa	cgcaattaa ^{at}	gtgagtt ^g tc	tca ^c tattaa	4260
	ggcacccca ^g	gctttacact	ttatgctcc	ggctcgat ^g	ttgtgtggaa	ttgtgac ^g cg	4320
	ataacaattt	cacacaggaa	acagctatga	ccatgattac	gccaagctct	ctagagctct	4380
10	agagctct ^g	agctctagag	agcttgc ^{at} g	ccggggta ^c c	agcttgc ^t g	ctagaacatc	4440
	atgttctggg	atatcagctt	cgtagctaga	acatcatgtt	ctggta ^c ccc	ggtc ^q a	4496

ctgttttgc	tcacccagaa	acgctggta	aagtaaaaga	tgctgaagat	cagttgggtg	2520
cacgagtggg	ttacatcgaa	ctggatctca	acagcggtaa	gatcctttag	agttttcgcc	2580
ccgaagaacg	tttccaatg	atgagcactt	ttaaagttct	gctatgtggc	gccccattat	2640
cccgattga	cgccggcaa	gagcaactcg	gtccggccat	acactattct	cagaatgact	2700
5 tgggttagta	ctcaccagtc	acagaaaagc	atcttacgga	tggcatgaca	gtaagagaat	2760
tatgcagtgc	tgccataacc	atgagtgata	acactgcggc	caacttactt	ctgacaacga	2820
tcgaggacc	gaaggagcta	accgctttt	tgccacaacat	gggggatcat	gtaactcgcc	2880
ttgatcggt	ggaaccggag	ctgaatgaag	ccataaccaa	cgacgagcgt	gacaccacga	2940
10 tgccctgtac	aatggcaaca	acgttgcgc	aactattaac	tggcaacta	cttactctag	3000
cttcccggca	acaattaata	gactggatgg	aggccgataa	agttgcagga	ccacttctgc	3060
gctcggccct	tccggctggc	tggtttattt	ctgataaatac	tggagccggt	gagcgtgggt	3120
ctcgccgtat	cattgcagca	ctggggccag	atggttaagcc	ctcccgatc	gtagttatct	3180
acacgacggg	gagtcaggca	actatggatg	aacgaaatag	acagatcgct	gagataggtg	3240
cctcaactgtat	taagcattgg	taactgtcag	accaagttt	ctcatatata	cttagattt	3300
15 attaaaaat	tcatttttaa	tttaaaagga	tctaggtaa	gatcctttt	gataatctca	3360
tgaccaaaaat	cccttaacgt	gagtttctgt	tccactgagc	gtcagacccc	gtagaaaaga	3420
tcaaaaggatc	ttcttgagat	ccttttttgc	tgccgttaat	ctgctgttt	caaacaaaaaa	3480
aaccaccgtt	accagcgggt	gtttttttgc	cggatcaaga	gctaccaact	cttttccga	3540
20 aggttaactgg	cttcagcaga	gcccgcatac	caaatactgt	ccttctatgt	tagccgtatg	3600
taggccacca	cttcaagaac	tctgttagcac	cgcctacata	cctcgctctg	ctaattctgt	3660
taccagtggc	tgctgcccgt	ggcgataagt	cgtgtcttac	cgggttggac	tcaagacgt	3720
agttaccgg	taaggcgcag	cggtcgggct	gaacgggggg	ttcgtgcaca	cagcccagct	3780
tggagcgaac	gacctacacc	gaactgagat	acctacagcg	tgagctatga	gaaagcgcca	3840
25 cgcttcccg	agggagaaag	gcccgcacgt	atccggtaag	ccgcagggtc	gaaacaggag	3900
agcgcacgag	ggagcttcca	gggggaaacg	cctggatct	ttatagtcct	gtcgggtttc	3960
gccacctctg	acttgagcgt	cgatttttgt	gatgctcg	agggggccgg	agcctatgga	4020
aaaacgcccag	caacgcggcc	tttttacgtt	tcctggcctt	ttgctggcct	tttgctcaca	4080
30 tggatctttcc	tgcggtatcc	cctgattctg	tggtataaccg	tattaccg	tttgagttag	4140
ctgataccgc	tcgcccgcag	cgaacgcacc	agcgcagcga	gtcagtgtac	gagggttacc	4200
agaacatgtat	gttctagcta	cgaagctgtat	atccagaac	atgatgttct	agctacgaa	4260
ctgttacccc	agcggaaag	cgcccaatac	gcaaaaccg	tctcccccgc	cgttggccga	4320
tttattatgt	cagctggcac	gacaggtt	ccgactggaa	agcggggcagt	gagcgcac	4380
caattatgtat	gagttagctc	actcattagg	caccggc	tttacactt	atgcttccgg	4440
35 ctcgtatgtt	gtgttggatt	gtgagcggat	aacaattca	cacagaaac	agctatgacc	4500
atgattacgc	caagctctt	agactctag	agcttagag	ctctagagag	cttgcatg	4560
ggggtaccag	cttcgtatgtt	agaacatcat	gttctggat	atcagcttcg	tagctagaac	4620
atcatgttct	ggtaccccg	tcga				4644

40 <210> 18
 <211> 933
 <212> PRT
 <213> Homo sapiens

45 <400> 18
 Met Thr Glu Leu Lys Ala Lys Gly Pro Arg Ala Pro His Val Ala Gly
 1 5 10 15

50 Gly Pro Pro Ser Pro Glu Val Gly Ser Pro Leu Leu Cys Arg Pro Ala
 20 25 30

Ala Gly Pro Phe Pro Gly Ser Gln Thr Ser Asp Thr Leu Pro Glu Val
 35 40 45

55 Ser Ala Ile Pro Ile Ser Leu Asp Gly Leu Leu Phe Pro Arg Pro Cys
 50 55 60

Gln Gly Gln Asp Pro Ser Asp Glu Lys Thr Gln Asp Gln Gln Ser Leu
 65 70 75 80

60 Ser Asp Val Glu Gly Ala Tyr Ser Arg Ala Glu Ala Thr Arg Gly Ala
 85 90 95

Gly Gly Ser Ser Ser Pro Pro Glu Lys Asp Ser Gly Leu Leu Asp
 100 105 110

5 Ser Val Leu Asp Thr Leu Leu Ala Pro Ser Gly Pro Gly Gln Ser Gln
 115 120 125

Pro Ser Pro Pro Ala Cys Glu Val Thr Ser Ser Trp Cys Leu Phe Gly
 10 130 135 140

Pro Glu Leu Pro Glu Asp Pro Pro Ala Ala Pro Ala Thr Gln Arg Val
 145 150 155 160

15 Leu Ser Pro Leu Met Ser Arg Ser Gly Cys Lys Val Gly Asp Ser Ser
 165 170 175

Gly Thr Ala Ala Ala His Lys Val Leu Pro Arg Gly Leu Ser Pro Ala
 180 185 190

20 Arg Gln Leu Leu Leu Pro Ala Ser Glu Ser Pro His Trp Ser Gly Ala
 195 200 205

Pro Val Lys Pro Ser Pro Gln Ala Ala Ala Val Glu Val Glu Glu Glu
 25 210 215 220

Asp Gly Ser Glu Ser Glu Glu Ser Ala Gly Pro Leu Leu Lys Gly Lys
 225 230 235 240

30 Pro Arg Ala Leu Gly Gly Ala Ala Ala Gly Gly Gly Ala Ala Ala Val
 245 250 255

Pro Pro Gly Ala Ala Ala Gly Gly Val Ala Leu Val Pro Lys Glu Asp
 260 265 270

35 Ser Arg Phe Ser Ala Pro Arg Val Ala Leu Val Glu Gln Asp Ala Pro
 275 280 285

Met Ala Pro Gly Arg Ser Pro Leu Ala Thr Thr Val Met Asp Phe Ile
 40 290 295 300

His Val Pro Ile Leu Pro Leu Asn His Ala Leu Leu Ala Ala Arg Thr
 305 310 315 320

Arg Gln Leu Leu Glu Asp Glu Ser Tyr Asp Gly Gly Ala Gly Ala Ala
 45 325 330 335

Ser Ala Phe Ala Pro Pro Arg Ser Ser Pro Cys Ala Ser Ser Thr Pro
 340 345 350

50 Val Ala Val Gly Asp Phe Pro Asp Cys Ala Tyr Pro Pro Asp Ala Glu
 355 360 365

Pro Lys Asp Asp Ala Tyr Pro Leu Tyr Ser Asp Phe Gln Pro Pro Ala
 55 370 375 380

Leu Lys Ile Lys Glu Glu Glu Glu Gly Ala Glu Ala Ser Ala Arg Ser
 385 390 395 400

60 Pro Arg Ser Tyr Leu Val Ala Gly Ala Asn Pro Ala Ala Phe Pro Asp
 405 410 415

Phe Pro Leu Gly Pro Pro Pro Pro Leu Pro Pro Arg Ala Thr Pro Ser
 420 425 430

5 Arg Pro Gly Glu Ala Ala Val Thr Ala Ala Pro Ala Ser Ala Ser Val
 435 440 445

Ser Ser Ala Ser Ser Ser Gly Ser Thr Leu Glu Cys Ile Leu Tyr Lys
 450 455 460

10 Ala Glu Gly Ala Pro Pro Gln Gln Gly Pro Phe Ala Pro Pro Pro Cys
 465 470 475 480

15 Lys Ala Pro Gly Ala Ser Gly Cys Leu Leu Pro Arg Asp Gly Leu Pro
 485 490 495

Ser Thr Ser Ala Ser Ala Ala Ala Gly Ala Ala Pro Ala Leu Tyr
 500 505 510

20 Pro Ala Leu Gly Leu Asn Gly Leu Pro Gln Leu Gly Tyr Gln Ala Ala
 515 520 525

Val Leu Lys Glu Gly Leu Pro Gln Val Tyr Pro Pro Tyr Leu Asn Tyr
 530 535 540

25 Leu Arg Pro Asp Ser Glu Ala Ser Gln Ser Pro Gln Tyr Ser Phe Glu
 545 550 555 560

30 Ser Leu Pro Gln Lys Ile Cys Leu Ile Cys Gly Asp Glu Ala Ser Gly
 565 570 575

Cys His Tyr Gly Val Leu Thr Cys Gly Ser Cys Lys Val Phe Phe Lys
 580 585 590

35 Arg Ala Met Glu Gly Gln His Asn Tyr Leu Cys Ala Gly Arg Asn Asp
 595 600 605

Cys Ile Val Asp Lys Ile Arg Arg Lys Asn Cys Pro Ala Cys Arg Leu
 610 615 620

40 Arg Lys Cys Cys Gln Ala Gly Met Val Leu Gly Gly Arg Lys Phe Lys
 625 630 635 640

Lys Phe Asn Lys Val Arg Val Arg Ala Leu Asp Ala Val Ala Leu
 645 650 655

45 Pro Gln Pro Leu Gly Val Pro Asn Glu Ser Gln Ala Leu Ser Gln Arg
 660 665 670

50 Phe Thr Phe Ser Pro Gly Gln Asp Ile Gln Leu Ile Pro Pro Leu Ile
 675 680 685

Asn Leu Leu Met Ser Ile Glu Pro Asp Val Ile Tyr Ala Gly His Asp
 690 695 700

55 Asn Thr Lys Pro Asp Thr Ser Ser Ser Leu Leu Thr Ser Leu Asn Gln
 705 710 715 720

60 Leu Gly Glu Arg Gln Leu Leu Ser Val Val Lys Trp Ser Lys Ser Leu
 725 730 735

Pro Gly Phe Arg Asn Leu His Ile Asp Asp Gln Ile Thr Leu Ile Gln
 740 745 750

Tyr Ser Trp Met Ser Leu Met Val Phe Gly Leu Gly Trp Arg Ser Tyr
 5 755 760 765

Lys His Val Ser Gly Gln Met Leu Tyr Phe Ala Pro Asp Leu Ile Leu
 770 775 780

10 Asn Glu Gln Arg Met Lys Glu Ser Ser Phe Tyr Ser Leu Cys Leu Thr
 785 790 795 800

Met Trp Gln Ile Pro Gln Glu Phe Val Lys Leu Gln Val Ser Gln Glu
 15 805 810 815

Glu Phe Leu Cys Met Lys Val Leu Leu Leu Asn Thr Ile Pro Leu
 820 825 830

20 Glu Gly Leu Arg Ser Gln Thr Gln Phe Glu Glu Met Arg Ser Ser Tyr
 835 840 845

Ile Arg Glu Leu Ile Lys Ala Ile Gly Leu Arg Gln Lys Gly Val Val
 850 855 860

25 Ser Ser Ser Gln Arg Phe Tyr Gln Leu Thr Lys Leu Leu Asp Asn Leu
 865 870 875 880

His Asp Leu Val Lys Gln Leu His Leu Tyr Cys Leu Asn Thr Phe Ile
 30 885 890 895

Gln Ser Arg Ala Leu Ser Val Glu Phe Pro Glu Met Met Ser Glu Val
 900 905 910

35 Ile Ala Ala Gln Leu Pro Lys Ile Leu Ala Gly Met Val Lys Pro Leu
 915 920 925

Leu Phe His Lys Lys
 930

40 <210> 19
 <211> 2970
 <212> DNA
 <213> Homo sapiens

45 <400> 19
 ctgaccagcg ccggccctccc ccggcccccga cccaggaggt ggagatccct ccgggtccagc 60
 cacattcaac acccaacttc tcctccctct gcccctatatat tccccaaacc ccctccctct 120
 tccctttcc ctcctccctg gagacggggg aggagaaaaag gggagttccag tcgtcatgac 180
 tgagctgaag gcaaagggtc cccgggctcc ccacgtggcg ggcggcccccgc cctccccca 240
 ggtcgatcc ccactgtgt gtcggccagc cgcaggtccg tttccgggga gccagacctc 300
 ggacacattt cctgaagggtt cggccatacc tatctccctg gacgggctac tttccctcg 360
 gccctgccag ggacaggacc cctccgacga aaagacgcag gaccaggact cgctgtcgga 420
 cgtggaggc gcattttca gagctgaagc tacaagggtt gctggaggca gcagttctag 480
 55 tccccccagaa aaggacagcg gactgctgga cagtgtctt gacactctgt tggcccccctc 540
 aggtccccggg cagagccaaac ccagccctcc cgcctgcgag gtcaccagct cttggtgct 600
 gtttggccccc gaacttccc aagatccacc ggctgcccc gcccacccagc ggggtttgtc 660
 cccgctcatg agccggtccg ggtgcaagggt tggagacagc tccgggacgg cagctgccc 720
 60 taaagtgtcg ccccggggccc tgcaccagc ccggcagctg ctgctccccc cctctgagag 780
 ccctcactgg tccggggccc cagtgaagcc gtctccgcag gccgctgcgg tggagggttga 840
 ggaggaggat ggctctgagt ccgaggagtc tgcgggtccg cttctgaagg gcaaaccctcg 900
 ggctctgggt ggcgcggcgg ctggaggagg agccgcggct gtcccgccgg gggcggcagc 960

5	aggaggcgtc	gccctggtcc	ccaaggaaga	ttcccgcttc	tcagcgccca	gggtcgccct	1020
	ggtgaggcag	gacgcgccga	tggcgcgg	gcgctccccg	ctggccacca	cggtgatgga	1080
	tttcatccac	gtgcctatcc	tgcctctcaa	tcacgcctta	ttggcagccc	gcaactcgca	1140
	gctgctggaa	gacgaaaagtt	acgacggcgg	ggccggggct	gccagcgct	ttgccccgcc	1200
10	gcggagttca	ccctgtgcct	cgtccacccc	ggtcgtgt	ggcgacttcc	ccgactgcgc	1260
	gtacccgccc	gacgcccggc	ccaaggacga	cgcgtaccc	ctctatagcg	acttccagcc	1320
	gcccgccta	aagataaaagg	aggaggagga	aggcgccgg	gcctccgcgc	gctccccgca	1380
	ttcctacctt	gtggccgggt	ccaaccccg	agcctcccg	gatttccgt	tggggccacc	1440
15	gcccccgctg	ccgcccggag	cgaccccatc	cagacccggg	gaagcgggg	tgacggccgc	1500
	acccgcctgt	gcctcagtct	cgtctgcgtc	ctcctcgggg	tcgacccctgg	agtgcatect	1560
	gtacaaaagcg	gaggggcgcc	cgcggccagca	gggcccgttc	gcgcgcgcgc	cctgcaaggc	1620
	gcccggcgcg	agcggctgcc	tgcctcccg	ggacggcctg	ccctccacct	ccgcctctgc	1680
20	cgccgcgcgc	ggggcgcccc	ccgcgtctca	ccctgcactc	ggcctaaca	ggtccccgca	1740
	gctcggtcac	caggccggcg	tgctcaagga	gggcctgcgg	caggtctacc	cgccctatct	1800
	caactacctg	aggccggatt	cagaagccag	ccagagccca	caatacagct	tcgagtcatt	1860
	acctcagaag	atttgtttaa	tctgtgggg	tgaagcatca	ggctgtcatt	atgtgtctt	1920
	tacctgtggg	agctgttaagg	tcttctttaa	gagggcaatg	gaagggcagc	acaactactt	1980
	atgtgttgg	agaaaatgact	gcatgttga	taaaatccgc	agaaaaaaact	gcccagcatg	2040
25	tcgccttaga	aagtgtgtc	aggtggcat	ggtccttgg	ggtcgaaaat	taaaaaagtt	2100
	caataaaagtc	agagttgtga	gagcaactgg	tgctgttgc	ctcccacagc	cattggcggt	2160
	tccaaatgaa	agccaagccc	taagccagag	attcaattt	tcaccaggc	aagacataca	2220
	gttGatttca	ccactgtatca	acctgttaat	gagcattgaa	ccagatgtg	tctatgcagg	2280
30	acatgacaac	acaaaacctg	acacccctcc	ttctttgtc	acaagtcata	atcaactagg	2340
	cgagaggcaa	cttcttcag	tagtcaagt	gtctaaatca	ttgcccagg	ttcgaaactt	2400
	acatattgtat	gaccagataa	ctctcattca	gtattttgg	atgagcttaa	tgggtttgg	2460
	tctaggatgg	agatcctaca	aatatgtcag	tgggcagatg	ctgtattttgc	cacctgtatct	2520
	aataactaaat	gaacagcgga	tggaaagaaatc	atcatatctat	tcattatgtcc	ttaccatgtg	2580
	gcagatccca	caggagtttgc	tcaagcttca	agttagccaa	gaagagttcc	tctgtatgaa	2640
	agtattgtta	cttcttaata	caattccctt	ggaagggcta	cgaaagtcaaa	cccagtttga	2700
	ggagatgagg	tcaagctaca	ttagagagct	catcaaggca	attggtttga	ggcaaaaagg	2760
	agtgtgtcg	agctcacacgc	gtttctatca	acttacaaaa	cttcttgata	acttgcata	2820
	tcttgcaaa	caacttcatac	tgtactgctt	gaatacattt	atccagttcc	gggcactgag	2880
	tgttgaattt	ccagaaatga	tgtctgaagt	tattgtcga	caattaccca	agatattggc	2940
35	aggatggtg	aaacccttc	tcttcataaa				2970

INTERNATIONAL SEARCH REPORT

In. National Application No
PCT/EP 00/01368

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/12	C12N15/57	C12N15/67	C12N15/85	C12N9/64
	C07K14/72	C12Q1/68	A61K48/00		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 28150 A (UNIV MCGILL) 8 December 1994 (1994-12-08) page 5, line 1 - line 11 page 6, line 34 -page 7, line 10 page 6, line 24. - line 28 page 10, line 20 - line 25 page 14, line 14 - line 19 claims 1-11 ---	1,2,6,7, 11,29,30
Y	page 5, line 1 - line 11 page 6, line 34 -page 7, line 10 page 6, line 24. - line 28 page 10, line 20 - line 25 page 14, line 14 - line 19 claims 1-11 ---	3-5,8,9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "S" document member of the same patent family

Date of the actual completion of the international search

6 June 2000

Date of mailing of the international search report

26/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/EP 00/01368

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	V. BOONYARATANAKORNKIT ET AL.: "High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells" MOL. CELL. BIOL., vol. 18, no. 8, August 1998 (1998-08), pages 4471-4487, XP002139580 ASM WASHINGTON, DC,US cited in the application the whole document	1,2,7
X	WO 94 17182 A (RES INST OF THE PALO ALTO MEDI ;LEAVITT JOHN C (US)) 4 August 1994 (1994-08-04) page 16, line 30 - line 36 page 17, line 1 - line 3; claims 1-16	1,2,6,7, 11,29,30
X	WO 93 20218 A (CONNAUGHT LAB ;FILMUS JORGE (CA); KLEIN MICHEL (CA)) 14 October 1993 (1993-10-14) the whole document	1,2,6,11
Y	WO 94 29471 A (GENETIC THERAPY INC) 22 December 1994 (1994-12-22) the whole document	3-5,8,9
A	WO 93 23431 A (BAYLOR COLLEGE MEDICINE) 25 November 1993 (1993-11-25) cited in the application the whole document	
A	BEATO M ET AL: "Transcriptional regulation by steroid hormones" STEROIDS: STRUCTURE, FUNCTION, AND REGULATION, US, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 61, no. 4, 1 April 1996 (1996-04-01), pages 240-251, XP004026583 ISSN: 0039-128X the whole document	
A	BEATO M: "GENE REGULATION BY STEROID HORMONES" CELL,US,CELL PRESS, CAMBRIDGE, MA, vol. 56, no. 3, 10 February 1989 (1989-02-10), pages 335-344, XP000051659 ISSN: 0092-8674 the whole document	
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/01368

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KURACHI S. ET AL: "Regulatory mechanism of human factor IX gene: Protein binding at the Leyden-specific region." BIOCHEMISTRY, (1994) 33/6 (1580-1591). , XP002139581 the whole document</p> <p>---</p>	
A	<p>CROSSLEY M. ET AL: "Recovery from hemophilia B Leyden: An androgen-responsive element in the factor IX promoter." SCIENCE, (1992) 257/5068 (377-379). , XP002139582 the whole document</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/01368

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9428150	A 08-12-1994	US 5512483	A	30-04-1996
		AU 6791894	A	20-12-1994
WO 9417182	A 04-08-1994	AU 6087694	A	15-08-1994
WO 9320218	A 14-10-1993	AU 3883393	A	08-11-1993
		BR 9306167	A	13-01-1998
		EP 0633941	A	18-01-1995
		FI 944451	A	26-09-1994
		JP 2701983	B	21-01-1998
		JP 7501456	T	16-02-1995
		NO 943610	A	30-11-1994
		US 5559027	A	24-09-1996
WO 9429471	A 22-12-1994	EP 0710288	A	08-05-1996
		JP 8511423	T	03-12-1996
		US 5935935	A	10-08-1999
WO 9323431	A 25-11-1993	US 5364791	A	15-11-1994
		AU 685054	B	15-01-1998
		AU 4241793	A	13-12-1993
		AU 6065198	A	02-07-1998
		CA 2135644	A	25-11-1993
		EP 0745121	A	04-12-1996
		JP 7509694	T	26-10-1995
		US 5935934	A	10-08-1999
		US 5874534	A	23-02-1999